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Abstract
In humans, the functional regulation of facilitative glucose transporters (GLUTs)
by insulin plays a central role in the maintenance of glucose homeostasis. The
insensitivity of tissues to this regulation results in diabetes mellitus, however, the
underlying mechanisms remain largely unknown. To establish Caenorhabditis elegans (C.
elegans) as a model system to study the mechanisms of insulin regulation of GLUTs
because of the well-conserved insulin/IGF-like signaling (IIS) and many unique
advantages of this organism, we functionally characterized 9 candidate genes of human
GLUT homologues in C. elegans based on their sequence homologies to GLUTs. We
found that FGT-1 is the only functional GLUT homologue with the ability to transport 2deoxy-D-glucose (2DG) in Xenopus oocytes. FGT-1 mediated 2DG transport could be
inhibited by the GLUT inhibitor phloretin and exhibited a Michaelis constant (Km) of 2.8
mM, which is smaller than the Km values of human GLUT1 and GLUT4. In addition to
glucose, FGT-1 could also transport mannose, galactose, and fructose. Using a FGT1::GFP fusion construct under the control of the 5 kb promoter sequence of the fgt-1a
gene, FGT-1 was shown to be ubiquitously expressed in C. elegans tissues and cells,
including the digestive tract, neurons, and body wall muscle. Two FGT-1 alternative
splicing isoforms, FGT-1A and FGT-1B, showed similar transport activity and tissue
localization.
To study the function of FGT-1 and its regulation by IIS, the changes in several
phenotypes that are known to be regulated by IIS were observed in FGT-1-knockdown
worms or null strains in the presence or absence of IIS activity. FGT-1 knockdown
resulted in fat accumulation but had no effects on dauer formation or brood size in both
wild-type and daf-2 (insulin receptor) gene mutant strains. However, the function of
FGT-1 in animal growth and aging was dependent on the IIS background, suggesting IIS
regulation of FGT-1 function. Consistently, FGT-1 mediated glucose uptake was almost
completely defective in the daf-2 and age-1 (PI3 kinase) mutants, and phloretin could
only marginally inhibit 2DG uptake in these strains. This defect was only partially related
to the approximately 60% decrease in FGT-1 protein levels in these mutants, suggesting
the involvements of both post-transcriptional and post-translational regulatory
mechanisms. We also found that OGA-1, an O-GlcNAcase, is essential for the function
of FGT-1, implying possible regulation of FGT-1 function by glycosylation.
In summary, our study has established C. elegans as a powerful model to study
the mechanism by which insulin regulates glucose transporters and has provided insights
into the mechanism of defective glucose uptake by tissues in patients with diabetes.
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Chapter 1: Literature Review
1.1 Introduction
The incidence of diabetes mellitus has increased in recent decades, particularly
in economically affluent countries, and now is gradually becoming widespread
worldwide. In 2010, approximately 347 million people had diabetes, and this number will
increase to 438 million people by 2030 (Rawal et al. 2012; Wang et al. 2015). Diabetes
severely affects the quality of life of patients and has high costs for both patients and
society. The estimated direct and indirect medical expenditure for diabetes treatment was
132 billion dollars in 2002 in the US alone (Hogan et al. 2003). Many efforts have been
made to develop effective drug treatments for diabetes. Although these attempts have
shown some positive results, the current medications remain insufficient to overcome
diabetes, and the number of diabetic patients is continuously increasing (Ginter and
Simko 2010; Narayan 2005; Parikh et al. 2011).
Diabetes is a metabolic syndrome characterized by high blood glucose levels.
Insulin is the major hormone that regulates blood glucose levels by stimulating glucose
uptake and utilization in peripheral tissues, such as muscle and fat. In type 1 diabetes,
pancreas β-cells is deteriorated because of autoimmune destruction, whereas in type 2
diabetes, the peripheral tissues establish insulin resistance and are not able to increase
glucose uptake in response to insulin stimulation. Importantly, insulin secretion is
defective in both conditions. Type 2 diabetes represents approximately 90% of total
diabetes incidence (WHO 2014). In diabetes patients, the amount of insulin-sensitive
1

glucose transporters expressed on the cell surface is closely related to the level of insulin
resistance (Garvey et al. 1998). Thus, understanding the regulatory mechanisms of
glucose homeostasis mediated by insulin signaling is critical for developing the proper
treatment for diabetes.

1.2 Regulation of glucose homeostasis in humans
The essential energy source glucose is a substrate for macromolecule synthesis
in most living organisms. Glucose is supplied primarily from the blood stream to most
tissues, although the synthesis of glucose by gluconeogenesis and the breakdown of
stored sugar by glycogenolysis can also meet glucose demands in some tissues, such as
liver and muscle (Vissing and Haller 2012; Rui 2014). The blood glucose level is strictly
regulated by endocrine hormones; excessively high or low blood glucose levels cause
several metabolic disorders (Kalsbeek et al. 2014). Insulin and glucagon are the dominant
hormones that control blood glucose levels, but several other hormones are also involved,
including growth hormone, glucocorticoids, and thyroid hormones. Although most of
these hormones are responsible for up-regulating blood glucose levels, insulin is the only
known hormone that lowers blood glucose concentrations (Yki-Järvinen 1993; Noguchi
et al. 2013). After food intake, ingested carbohydrates are digested, absorbed from the
gastrointestinal tract, diffused to the blood stream, and circulated around the body. The
increased blood glucose level stimulates the β-cells in the islets of Langerhans of the
pancreas to secrete insulin (Lindsay et al. 2003). Insulin decreases blood glucose by
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stimulating cellular glucose uptake, glycolysis, and glycogenesis (Probst and UnthanFechner 1985; Srivastava and Pandey 1998) and by inhibiting glucose production by
gluconeogenesis and glycogenolysis in the liver, muscle, or adipose tissues (Sutherland et
al. 1996; Bollen et al. 1998). The stimulation of glucose uptake primarily in muscle and
fat tissues plays a key role in decreasing blood glucose levels; this stimulation is
mediated by the activation of glucose transporter proteins. Because of the hydrophilic
property of glucose, carrier proteins are essential for transporting glucose through the
plasma membrane of cells. Insulin secretion disruption or tissue insulin sensitivity are the
major causes of diabetes (Wang et al. 2015; Ma et al. 2015).
In contrast, when people are in a fasting state, decreased blood glucose levels
induce the α-cells of the islets of Langerhans of the pancreas to release glucagon.
Glucagon inhibits glycolysis and activates gluconeogenesis and glycogenolysis in the
liver to supply additional glucose to the blood stream (Bazotte et al. 1988; Exton et al.
1972). The primary control of glucagon secretion is mediated by glucose-sensitive neural
stimulation. Pancreas α-cells are innervated by the sympathetic nervous system, which
stimulates glucagon secretion by the neurotransmitter norepinephrine, and this
stimulation is effectively blocked by neuropeptide Y (Ahrén 2000; Pettersson et al.
1987). Unlike the function of insulin, no evidence indicating that glucagon directly
regulates the activity of glucose transporters in any tissues have been found. Recently,
glucagon excess was found to be as important as insulin deficiency in diabetes, thus, this
hormone has also been targeted in therapeutic studies of diabetes (Unger and Cherrington
2012). Other hormones such as growth hormone and glucocorticoids also activate
3

anabolic glucose reactions in their target cells, however, the activation of these reactions
accelerates metabolism of the target cell and does not supply glucose to the blood stream.

1.3 Mammalian glucose transporters
Thus far, three families of glucose transporters have been identified in
mammals. The facilitative glucose transporter (GLUT) family mediates glucose diffusion
across the plasma membrane in passive manner along its concentration gradient (Thorens
and Mueckler 2010; Zhao and Keating 2007). Glucose uptake in most tissues and cells is
performed by this family of transporters. The Na+/glucose cotransporter (SGLT) family
mediates active transport, which allows the transport of glucose against its concentration
gradient (Castaneda-Sceppa and Castaneda 2011). The major roles of this family of
transporters are to absorb monosaccharides from the intestinal lumen and to reabsorb
glucose from the proximal tubules of the kidney. The SWEET (Sugars Will Eventually be
Exported Transporters) family has recently been discovered and has a possible function
in the cellular sugar efflux in human cells (Chen et al. 2010).
1.3.1 Facilitative glucose transporters (GLUTs)
Currently, 14 isoforms of GLUTs have been reported in humans (Table 1); these
isoforms have high sequence similarity and share common structural characteristics such
as 12 transmembrane domains, an N-glycosylation site on the first or fifth loop, and sugar
transporter signatures (Zhao and Keating 2007; Sun et al. 2012). Despite the well
conserved common structures among GLUT isoforms, individual transporters have
4

different transport kinetics, sugar specificities, and tissue distribution (Zhao and Keating
2007). Amino acid sequence differences roughly classify GLUT members into three
groups: classes I, II, and III. Class I and II GLUTs contain a longer extracellular loop 1
with a conserved N-linked glycosylation site. Class III family members have a large loop
with a glycosylation site on the fifth extracellular loop instead of the first loop, and their
first loop is relatively short (Augustin 2010; Zhao and Keating 2007).
1.3.2 Class I
The class I GLUT family consists of GLUT1-4 and GLUT14 (Thorens and
Mueckler 2010; Mueckler and Thorens 2013). GLUT1 is the most ubiquitously expressed
isoform and mediates glucose transport by itself or with other GLUT isoforms in
individual tissues, making this isoform the “general” glucose transporter. GLUT1, which
was originally isolated from erythrocytes, abundantly localizes in the red blood cells to
enhance their capacity to carry glucose for circulation (Mueckler and Thorens 2013).
GLUT1 is also expressed in high levels in the endothelial and epithelial-like barriers of
the brain, eyes, brain astrocytes, peripheral nerve, and placenta (Illsley 2000; Takata et al.
1990; Pellerin et al. 2002). In a Xenopus laevis oocyte model, GLUT1 shows transport
activity, with Michaelis constant (Km) values of 5-11 mM for 2-deoxy-D-glucose (2DG)
(Vera and Rosen 1989; Bentley et al. 2012) and of 3 mM for glucose (Uldry et al. 2002).
In addition to glucose, this transporter has the capacity to transport galactose, mannose,
and glucosamine (Uldry et al. 2002; Carruthers et al. 2009; Bentley et al. 2012). N-linked
glycosylation, which is a structural characteristic of the GLUT family, is indispensable
for the high affinity of GLUT1 for glucose (Asano et al. 1991).
5

GLUT2 is a low-affinity, high capacity GLUT that has the highest Km for
glucose (~17 mM) among GLUT family members (Johnson et al. 1990). GLUT2 also
transports galactose, mannose, and fructose with low affinity (Johnson et al. 1990).
Interestingly, this transporter shows a high affinity for glucosamine (Km = 0.8 mM)
(Uldry et al. 2002). The major site of GLUT2 localization is hepatocytes, where GLUT2
takes up glucose and fructose after feeding and releases glucose in a fasted state (Guillam
et al. 1998). In intestine cells, GLUT2 primarily mediates glucose diffusion to the blood
stream on the basolateral membrane (Fukumoto et al. 1988), however, GLUT2 can also
be translocated to the apical membrane for glucose absorption, depending on the
availability of glucose and fructose in the intestinal lumen (Kellett et al. 2008; Leturque
et al. 2009). GLUT2 is also expressed in the basolateral membrane of the epithelial cells
of proximal convoluted tubules in the kidney and is involved in glucose reabsorption
mediated by SGLT transporters (Guillam et al. 1998).
GLUT3 is considered a neuron-specific glucose transporter because of its
prominent localization in the brain (Shepherd et al. 1992; Haber et al. 1993; McCall et al.
1994). The high affinity of GLUT3 for glucose (Km = 1.4 mM for 2DG) (Manolescu et al.
2007) is essential for its expression in the brain because the glucose concentration in the
brain is particularly lower compared to that in the blood. GLUT3 is also localized in the
testis, placenta, embryo, and white blood cells, which are all tissues with high demands
for glucose (Illsley 2000; Pantaleon et al. 1997; Simpson et al. 2008). The other
substrates of GLUT3 are galactose, mannose, maltose, and xylose, but not fructose
(Colville et al. 1993). GLUT14, another class I GLUT family member, was identified as a
6

gene duplication product of GLUT3 (95% identical to the nucleotide sequence of
GLUT3) (Wu and Freeze 2002). GLUT14 is localized primarily in the testis.
GLUT4 is one of the most widely studied glucose transporters because it
mediates insulin-regulated glucose uptake in muscle cells and adipocytes. In these cells,
insulin stimulates GLUT4 translocation from the intracellular pool to the plasma
membrane, thus increasing glucose uptake and utilization (Leto and Saltiel 2012; Saltiel
and Kahn 2001). This regulation plays a critical role in maintaining whole body glucose
homeostasis (Leto and Saltiel 2012). For GLUT4, N-glycosylation is important for the
translocation machinery, however, it plays no major role in GLUT4 transport activity
(Zaarour et al. 2012; Haga et al. 2011). Although the major localization of GLUT4 is in
the muscle and adipose tissues, GLUT4 is also expressed in some CNS neurons together
with GLUT3 to increase glucose uptake for high energy demand in specific neurons
(Apelt et al. 1999). GLUT4 transport affinity for glucose is similar to that of GLUT1 (Km
= 5-6 mM), and dehydroascorbic acid and glucosamine are also substrates of GLUT4
(Uldry et al. 2002; Kasahara and Kasahara 1997). The detailed mechanisms of GLUT4
regulation are discussed later.
1.3.3 Classes II and III
GLUT5, 7, 9, and 11 are included in the class II GLUT family. This class is
characterized by its fructose transport activity. Indeed, GLUT5 is the major fructose
transporter in human. The hydrophobic NXV/NXI sequence motif in helix 7 is known to
be important for fructose recognition, and this motif is conserved among class II isoforms
(Manolescu et al. 2007). GLUT5 and 7 are localized primarily in the apical membrane of
7

the small intestine for fructose and glucose uptake (Li et al. 2004; Barone et al. 2009).
GLUT9 functions in the kidney, liver, and pancreatic β-cells. GLUT9 knockdown by
siRNA reduces glucose-stimulated insulin secretion in mice and rats (Evans et al. 2009).
GLUT11 is a muscle-specific transporter that is dominantly expressed in the heart and
skeletal muscles (Scheepers et al. 2005; Doege et al. 2001). Interestingly, GLUT9 and 11
have alternative splicing and promoter usage, which is unique in the GLUT family,
resulting in splicing isoform-specific tissue distribution (Augustin et al. 2004; Scheepers
et al. 2005).
The class III family members GLUT6, 8, 10, 12, and 13 have some unique
structures. As above-described, class III GLUTs have an N-glycosylation site in
extracellular loop 5 rather than in loop 1. In addition, all class III isoforms contain an
internalization signal that sequesters transporters in intracellular vesicles. The consensus
internalization motifs are a YSRI motif for GLUT10 (Dawson et al. 2001; Augustin
2010) and a dileucine motif for other members (Lisinski et al. 2001; Flessner and Moley
2009; Zhao and Keating 2007). Although one study showed that intracellular vesicles
containing GLUT8 were successfully induced by insulin to translocate to the plasma
membrane (Carayannopoulos et al. 2000), various studies have contradicted this result
(Lisinski et al. 2001; Widmer et al. 2005; Augustin et al. 2005; Shin et al. 2004),
suggesting that class III GLUTs are not insulin-regulated transporters but function in
intracellular sugar trafficking. GLUT8 is localized in a late-endosomal/lysosomal
compartment inside cells in the testis (Diril et al. 2009), synaptic dense core vesicles of
nerve terminals, and secretory granules in the brain (Ibberson et al. 2002). GLUT12
8

contains a dileucine motif similar to that of GLUT8, however, this transporter localizes in
the Golgi apparatus and plasma membrane (Flessner and Moley 2009). GLUT6 and 10
also show internal localization, although no detailed sub-cellular localization study has
been performed. All these members have specificity for glucose (Zhao and Keating 2007;
Mueckler and Thorens 2013). GLUT13, also known as HMIT, is a unique transporter that
does not transport glucose despite its conserved protein structure containing all motifs
known to be important for glucose transport activity. Instead, the major substrate of
GLUT13 is myo-inositol since this isoform is a H+/myo-inositol co-transporter.
1.3.4 Na+/glucose cotransporters (SGLTs)
The SGLT family of proteins shares structural characteristics of 14
transmembrane domains and sodium:solute symporter family signature domains (Zhao
and Keating 2007). These members localize primarily in the intestine or kidney. SGLTs
expressed in the intestines mediate sugar absorption from the intestinal lumen, and
transporters expressed in the kidneys function in the reabsorption of monosaccharides
from the proximal convoluted tubules. SGLT1 is the major SGLT expressed in intestinal
cells (Wright et al. 1992), whereas SGLT2 is the major kidney isoform. Specific
inhibitors of SGLT2 have been developed for diabetes medication (Jung et al. 2014).
Human SGLT3 does not show transport activity for glucose but functions as a glucose
sensor (Diez-Sampedro et al. 2003). Interestingly, a single point mutation of SGLT3 on
the sugar interaction site sufficiently recovered the glucose transport activity of SGLT3
(Bianchi and Díez-Sampedro 2010).
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1.3.5 SWEETs
A new family of sugar transporters called the SWEET family was recently
identified in plants (Chen et al. 2010). This transporter family is found to be conserved in
plants, bacteria, and metazoans, including humans (Chen et al. 2010; Xu et al. 2014). The
SWEET family of proteins has only seven transmembrane domains and primarily
mediates cellular sugar efflux because the expression of human SWEET1 in yeast and
oocytes promotes only sugar efflux (Wright 2013). This transporter family is localized
systemically in plants and in the oviduct, epididymis, intestine, and lactating mammary
gland in mammals (Chen et al. 2010). Surprisingly, bacterial and fungal pathogens and
symbiotes of plants highjack this transporter family to acquire glucose from their hosts
(Chen et al. 2010). This new class of sugar transporters may have major glucose transport
functions in plants but most likely supports GLUT and SGLT families in cellular sugar
efflux in animals. The human GLUT, SGLT, and SWEET family transporters are
summarized in Table 1.1.

1.4 Regulation of glucose transport by insulin and its role in type 2
diabetes
1.4.1 Insulin secretion and signal transduction
Insulin is a protein hormone that is secreted from pancreatic β-cells and that is
encoded by a single-copy INS gene in humans. The INS gene first encodes a precursor of
insulin known as preproinsulin. Preproinsulin is a 110 amino acid protein that consists of
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a 21 amino acid A chain, a 30 amino acid B chain, a 31 amino acid C chain, and a signal
peptide on the N-terminus. The signal peptide guides the translocation of preproinsulin
into the endoplasmic reticulum lumen and is then cleaved by a signal peptidase to form
proinsulin (Chan et al. 1976; Patzelt et al. 1978). Then, proinsulin forms a three
dimensional structure with three disulfide bonds between its A and B chains (Huang and
Arvan 1995). The folded proinsulin is transported to the Golgi apparatus where its C
chain is cleaved to produce mature insulin and C-peptide (Huang and Arvan 1995). In
contrast to insulin, the function of C-peptide has not been known for a long time,
however, current studies have highlighted C-peptide as another therapeutic target for
diseases including diabetes because this hormone appears to play important roles in antiinflammatory, anti-oxidant, and cell protective mechanisms (Wahren and Larsson 2015).
Insulin secretion is dependent on the plasma glucose concentration (Schmitz et
al. 2008). β-cells form clusters that localize along capillaries surrounding pancreas islets,
allowing the rapid sensing of nutrients such as glucose in the blood and the diffusion of
insulin into the circulation (Suckale and Solimena 2008). β-cells are activated by several
nutrients, such as glucose, other monosaccharides, amino acids, and fatty acids, however,
the amplitude of β-cell induction is much larger for glucose compared to amino acids or
fatty acids (Chang and Goldberg 1978). GLUT2 participates in the first step of blood
glucose sensing mechanisms. Because GLUT2 is the dominant glucose transporter
expressed in β-cells, glucose diffusion into β-cells is largely dependent on GLUT2
function in humans. After glucose is taken up, it is metabolized inside cells and promotes
closure of ATP-sensitive potassium channels by increasing the intracellular ATP/ADP
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ratio, which subsequently opens voltage-dependent Ca2+ channels to promote the
exocytosis of insulin-containing granules (Maechler and Wollheim 1999; Bender et al.
2006). Some amino acids can also be directly incorporated into the tricarboxylic acid
(TCA) cycle to accelerate exocytosis (Sener and Malaisse 1980). In addition, dietary
amino acid can also activate insulin secretion through gastric inhibitory polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1) because these incretin hormones stimulate βcells directly by binding to their specific receptors on these cells (MacDonald et al.
2002b, 2002a). Free fatty acids also stimulate insulin secretion via signaling from FFAR1
(free fatty acid receptor 1) activation (Feng et al. 2012; Kristinsson et al. 2013).
In insulin target cells, insulin binds to the extracellular domain of the insulin
receptor (IR), which is the α-subunit of IR, leading to the phosphorylation of its
intracellular tyrosine kinase domain on its β-subunit, which allows IR to serve as a
docking site for many proteins, including IR substrate (IRS) proteins (Lizcano and Alessi
2002). IRS proteins trigger the activation of phosphatidylinositol 3-kinase (PI3K) by
assembling

its

regulatory

and

catalytic

subunits.

Active

PI3K

converts

phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to phosphatidylinositol-3,4,5triphosphate (PIP3), which is the second messenger of this pathway. Phosphatase and
tension homologue (PTEN) negatively regulates the insulin signaling cascade by
counteracting this PI3K conversion (Gupta and Dey 2012). This modulation permits the
fine-tuning of second messenger levels. PIP3 recruits phosphoinositide-dependent kinase
(PDK) 1 and 2 to the plasma membrane, and each isoform of PDK phosphorylates
different sites of Akt/protein kinase B (PKB) (Cantley 2002; Hodgkinson et al. 2002).
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mTORC2, which is a protein complex in the mTOR cascade, also phosphorylates the
same phosphorylation site of Akt as PDK2 (Sarbassov et al. 2005; Chen and Sarbassov
2011). Akt activation phosphorylates AS160 and inhibits its Rab-GAP activity,
promoting GLUT4 translocation to the plasma membrane (Lizcano and Alessi 2002;
Hoffman and Elmendorf 2011; Smith et al. 2011). In addition, Akt phosphorylates FOXO
(O class of forkhead box) 1 transcription factor to retain it in the cytosolic region as a
transcriptionally inactive protein (Van Der Heide et al. 2004). Although a defect in Akt
and AS160-mediated GLUT4 translocation is thought to be the dominant factor of insulin
resistance, FOXO1 is also a key factor in diabetes because constitutively active FOXO1
expression in the liver is sufficient for causing insulin resistance (Zhang et al. 2002; Lu et
al. 2012).
1.4.2 Subcellular translocation of GLUT4 and its regulation by insulin
GLUT4 is the major transporter that mediates insulin-regulated glucose uptake
in tissues (Augustin 2010; Leney and Tavaré 2009). This transporter is normally located
on intracellular microsomes in the absence of insulin stimulation, and once insulin
signaling becomes active, GLUT4 storage vesicles (GSVs) translocate from intracellular
compartments into the plasma membrane (Silverman et al. 2009), resulting in GLUT4
translocation to the cell surface to take up glucose. Because this step is one of the key
steps that is compromised in insulin resistance observed in diabetes, great efforts have
been made to reveal the regulatory mechanisms of GLUT4 translocation for over 20
years. Although the mechanisms remain far from clear, recent investigations have
revealed several key molecular systems involved in this process. The cell surface
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localization of GLUT4 is tightly regulated by balancing the levels of GSV exocytosis and
endocytosis. Under conditions with no insulin, slow exocytosis and rapid endocytosis of
GSVs retain surface transporter levels at less than 5% of total GLUT4 pools (Muretta et
al. 2008; Slot et al. 1991), and the balance is switched by insulin stimulation to increase
GLUT4 levels on the plasma membrane.
Upon insulin signaling, PI3K activates two different downstream cascades, Racand Akt-mediated pathways. Although many signaling molecules of GSV translocation
are regulated by Akt, Rac1/Rho GTPase is also a key player for the mechanical
mobilization of GSVs (Klip et al. 2014). Rac1 activation is required for actin remodeling.
The activities of the actin branching complex Arp2/3 and the actin filamentdepolymerizing enzyme cofilin are regulated by Rac1 for cell membrane remodeling by
dynamic actin cycling (Chiu et al. 2010). How the actin cycling mechanisms interact with
GLUT4 mobilization remains unclear, however, GSV polarization beneath the plasma
membrane requires actin cycling (Tong et al. 2001; Sun et al. 2010; Talior-Volodarsky et
al. 2008).
During GLUT4 translocation, the downstream target of Akt is AS160, a
GTPase-activating protein (GAP) of the Rab family (Mîinea et al. 2005). AS160 is a
regulatory protein that inhibits several Rab GTPases in the GLUT4 exocytosis pathway
(Sano et al. 2007; Sun et al. 2010). AS160 is the central regulator of GLUT4
translocation because the expression of constitutively active AS160 in adipocytes and
muscle cells prevents insulin-dependent GLUT4 translocation (Chen et al. 2012; Sun et
al. 2010). In contrast, the siRNA-mediated inhibition of AS160 significantly increased
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membrane GLUT4 localization without insulin stimulation (Ishikura et al. 2007). The
identification of AS160-targeted Rab GTPases is being actively investigated because
more than 60 Rab GTPases exist in the human genome (Stenmark and Olkkonen 2001).
Recently, Rab8A and Rab13 have been identified as the targets of AS160 in muscle cells
(Sun et al. 2010; Ishikura and Klip 2008). Additionally, Rab10 was found to be
indispensable for GLUT4 translocation in adipocytes, although a direct interaction
between AS160 and Rab10 has not been confirmed thus far (Sano et al. 2007). When
insulin signaling is activated, AS160 GAP activity is blocked, and the downstream Rab
proteins are ready to be activated. At this point, guanine nucleotide exchange factor
(GEF) function is required for the activation of Rab GTPases. GEFs containing DENN
(differentially expressed in normal and neoplastic cells) domain proteins DENND4A-C
were found to interact with Rab10 (Yoshimura et al. 2010). DENND4C knockdown
successfully inhibited the surface expression of GLUT4 under insulin activation (Sano et
al. 2011). Rabin8/Sec2p, GRAB, and DEEND1C are the known GEFs of Rab8A,
although which of these GEFs is incorporated in the insulin-regulated GLUT4 pathway is
unknown (Guo et al. 2013; Blümer et al. 2013). The identification of GEFs for Rab13
remains under investigation. Activated Rab proteins are capable of driving the motor
protein myosin 5a (Roland et al. 2009). While GLUT4 is translocated, GSVs are
trafficked by this myosin molecule along the actin cytoskeleton since myosin can interact
with actin filaments through their head groups (Semenova et al. 2008). After GSVs are
intracellularly trafficked, they are tethered to the plasma membrane. Although no direct
observations have been made, the molecular tracking of GSVs with total internal
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reflection fluorescence (TIRF) microscopy in myocytes indicated that Rac1-regulated
cortical actin filaments and myosin 5a-driven GSVs are tethered by myosin 1c and αactinin 4 function (Boguslavsky et al. 2012; Talior-Volodarsky et al. 2008). GSV
trafficking and dynamic actin sorting at the cell periphery are both regulated by insulin
signaling, while GSV membrane tethering with myosin 1c and α-actinin 4 is thought to
be a passive mechanism. The final step of GSV exocytosis is the membrane insertion of
these compartments. SNARE proteins are present on both GSVs and the plasma
membrane to promote the membrane fusion process. VAMP2 is a v-SNARE protein
localized on GSVs, and the t-SNARE protein syntaxin 4 is localized on the plasma
membrane with the plasma membrane-associated accessory protein synaptosomalassociated protein 23 (SNAP23) (Foster and Klip 2000; Randhawa et al. 2004;
Kawaguchi et al. 2010). The regulation of this fusion step by insulin remains under
investigation, however, the SNARE regulatory protein Munc18 has been implicated as a
target of insulin (Khan et al. 2001; Bryant and Gould 2011).
Internalization by endocytosis is another key pathway of GLUT4 translocation,
but this step has not been as well studied as exocytosis because insulin may have a minor
effect or no effect on endocytosis (Foster et al. 2001; Leto and Saltiel 2012). GLUT4 is
internalized in muscle cells by clathrin-mediated endocytosis and in adipose cells by both
clathrin-mediated and cholesterol-dependent endocytosis. Clathrin-mediated endocytosis
is not regulated by insulin signaling (Blot and McGraw 2006). In adipose tissues, insulin
decreases the rate of GLUT4 endocytosis (Blot and McGraw 2006; Czech and Buxton
1993). The regulatory mechanism may be mediated by switching cholesterol-dependent
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endocytosis to clathrin-mediated endocytosis to delay GLUT4 internalization under
active insulin conditions (Blot and McGraw 2006).
1.4.3 Other mechanisms by which insulin regulates GLUTs
The regulation of GLUT4 activity by insulin is not driven only by subcellular
translocation. In type 2 diabetes, insulin-stimulated GLUT4 translocation decreases but
the expression level of GLUT4 does not change in muscle tissues (Shepherd and Kahn
1999; Graham and Kahn 2007), however, both GLUT4 translocation and GLUT4
expression levels decrease in adipose tissue (Shepherd and Kahn 1999). Moreover, recent
research has shown that insulin may also increase GLUT4 transcription in muscle cells
(Moraes et al. 2014). GLUT4 expression is controlled by several different transcription
factors including MyoD, MEF2A, NFKB1, TNF-α, SREBP-1c, O/E-1, and NF-1 (Im et
al. 2007). O/E-1 and NF-1 bind to insulin response elements on the GLUT4 gene
promoter and regulate GLUT4 expression levels in an insulin-responsive manner (Cooke
and Lane 1999; Miura et al. 2004; Dowell and Cooke 2002). MEF2A and MyoD are
known to be up-regulated by insulin and to bind to AT-rich and E-box elements in the
GLUT4 promoter region, respectively, to increase GLUT4 transcription (Moraes et al.
2014). Zinc finger protein 407 (ZFP407) increases the transcription level, splicing
efficiency, and mRNA stability of GLUT4 in adipose tissue (Buchner et al. 2015).
Therefore, these studies have revealed that transcriptional regulation may also be an
important component of the regulation of GLUT4 function by insulin.
GLUT3 function in white blood cells is partially regulated by insulin. GLUT3 is
normally localized in intracellular vesicles in white blood cells but translocates to the
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plasma membrane by various proliferative stimuli including insulin stimulation
(Daneman et al. 1992; Simpson et al. 2008). These translocation stimuli function in a cell
type-specific manner; for instance, insulin stimulation can trigger GLUT3 activation in
B-lymphocytes and monocytes but not in neutrophils or T-lymphocytes (Daneman et al.
1992; Estrada et al. 1994; Maratou et al. 2007). This insulin- and other stimuli-activated
translocation should play a role in immune responses rather than in blood glucose
homeostasis regulation (Simpson et al. 2008).
GLUT2-mediated glucose efflux in the liver is indirectly regulated by insulin.
GLUT2 is plentifully expressed on the hepatocyte plasma membrane under low blood
glucose conditions primarily to release glucose produced in hepatocytes. When the blood
insulin level increases in the fed state, glucose catabolism is accelerated in the liver
(Saltiel and Kahn 2001), and receptor-bound insulin is endocytosed into hepatocytes for
insulin clearance from the circulation (Di Guglielmo et al. 1998). GLUT2 is concurrently
internalized inside the cell (Eisenberg et al. 2005). Intriguingly, IR and GLUT2
physically interact during internalization so that IR and GLUT2 form a receptortransporter complex when they are endocytosed by insulin activation (Eisenberg et al.
2005). Thus, GLUT2-mediated glucose efflux is blocked in a high blood glucose state by
insulin-regulated internalization mechanisms.
The insulin pathway is not the only GLUT regulatory mechanisms but there are
several different expression control systems of GLUT genes. For instance, tumor cells
require high glucose uptake which is mediated by GLUT function and the expression
stimulation is triggered by several factors such as hypoxia, estradiol, and epidermal
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growth factor (Macheda et al. 2005).

1.5 Caenorhabditis elegans (C. elegans)
C. elegans is a small soil nematode, a multiple-organ animal that has been used
as an in vivo laboratory model organism for biological and medical studies (Brenner
1974; Kaletta and Hengartner 2006). C. elegans have short reproductive cycles (3 days)
and lifespans (3 weeks), with large brood sizes (300 progenies/adult) (Brenner 1974). In
harsh environments, worms enter into an alternative developmental stage called the dauer
stage; dauer larvae can survive more than three months without energy sources (Cassada
and Russell 1975). The predominant sex of this worm is hermaphrodite, where the male
population is less than 0.1% of the total population under normal conditions. Severe
environmental conditions increase the male population to more than 1% for efficient
mating to enhance genetic diversity. Their cell lineage was fully described in early
studies (Sulston et al. 1983; Sulston and Horvitz 1977). The C. elegans hermaphrodite
loses 131 cells by apoptosis during embryonic and early larval (L2) stages, and the adult
hermaphrodite is finally composed of 959 cells (somatic nuclei) (Sulston et al. 1983;
Sulston and Horvitz 1977). This worm has several organs and systems, including a
nervous system, intestine, muscle, hypoderm, secretory-excretory system, gonads, and
uterus. The neuronal connectivity of this organism is also fully understood, the nervous
systems of hermaphrodites and males are composed of 302 and 391 neurons, respectively
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(Sulston and Horvitz 1977; Sulston et al. 1983). The worm body is transparent
throughout its lifespan.

1.6 C. elegans as a model system for biomedical research
The C. elegans worm has several advantages for biological studies and for drug
discovery. Their small body size (~1 mm in length) allows for easy maintenance in the
laboratory and handling in 96- or 384-well plates for high throughput analysis. Their
simple and short life cycle can accelerate experimental speeds (Brenner 1974). Their
transparent body at all developmental stages allows the visualization of all cells under
light and fluorescent microscopes. The knowledge of its complete cell lineage enhances
detailed microscopic analyses. The completely sequenced C. elegans genome harbors
~20,000 predicted coding genes that show homology to 60-80% of human genes
(Kuwabara and O’Neil 2001; C. elegans Sequencing Consortium 1998). Moreover,
plentiful forward and reverse genetic approaches are available. Gene knockout and
mapping methods are relatively easy in worms, and a large collection of mutant strains is
stocked

and

readily

accessible

(http://www.cbs.umn.edu/cgc)

from
and

the

Caenorhabditis

National

Genetic

Bioresource

Center
Project

(http://www.shigen.nig.ac.jp/c.elegans/). RNAi techniques, which were discovered in C.
elegans research (Fire et al. 1998), are easy to apply to C. elegans, and the whole genome
collection of synthesized dsRNAs or feeding bacteria expressing specific dsRNAs are
readily available (Tabara et al. 1998; Kamath et al. 2001).
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The high conservation of disease pathways and genes between C. elegans and
humans and the unique advantages described above make C. elegans an ideal and
effective in vivo model for disease pathway identification and high-throughput compound
screening. Of the current animal models, C. elegans is the most cost-effective highthroughput model (Kaletta and Hengartner 2006; Silverman et al. 2009). Although nonmammalian systems sometimes do not provide direct correspondence to human diseases,
the effort- and cost-effectiveness of the worm model make it an efficient system to begin
studying novel pathways and screening compounds in combination with later validation
steps in mammalian models.
1.6.1 Genetic analysis of disease pathways
C. elegans is widely used in basic studies of molecular pathways related to
human diseases such as metabolic syndrome, oncology, and neurodegeneration, as well
as several genetic diseases (Kaletta and Hengartner 2006). One of the advantages of C.
elegans is its fully characterized cell lineage description. Apoptosis is known as a cellular
response that is associated with several conditions including infection, tissue
degeneration, malignancy, and immunity (Lockshin and Zakeri 2007; Wang 2014;
Pasparakis and Vandenabeele 2015). Apoptotic cell characterization and their cell death
timing are fully understood in C. elegans, making C. elegans a good model for the study
of programmed cell death-associated disease pathways. To identify the genes involved in
the apoptosis pathway, forward genetic screening using ethyl methane sulfonate (EMS)
as a mutagen was employed, and mutant worms with disrupted programmed cell deaths
were screened. This screening resulted in the identification of loss-of-function mutations
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in ced-3 and ced-4, which are homologues of human caspases and apoptotic protease
activating factor-1 (APAF-1), respectively (Ellis and Horvitz 1986; Hedgecock et al.
1983; Conradt and Xue 2005). In the same manner, further genetic screening revealed the
central apoptotic factors CED-9/Bcl2 and EGL-1/BH3-only (Bcl2 homology domain-3)
proteins (Hengartner et al. 1992; Trent et al. 1983). Currently, these factors are
considered central regulators of the programmed cell death pathway.
Parkinson’s disease (PD) is another prominent example of a disease model using
C. elegans. The loss of dopamine neurons and aggregation of proteins (Lewy bodies) are
recognized as pathological characteristics of PD (Kuwahara et al. 2008). In C. elegans,
hermaphrodites have only eight dopamine neurons, whereas thousands of dopamine
neurons are present in the midbrain in mammals (Nass et al. 2002). The simplicity of C.
elegans enables comprehensive analyses of basic molecular mechanisms. Moreover,
transgenic worms expressing GFP specifically in dopamine neurons can allow the
number of dopamine neurons in intact animals to be visualized because of their
transparent bodies (Nass et al. 2001). A forward genetic analysis that used GFP
transgenic worms to screen for mutants resistant to neurotoxin 6-hydroxydopamine (6OHDA) identified several mutations in dat-1, a dopamine transporter gene (Nass et al.
2005). Another forward genetic screen was recently performed and revealed two novel
alleles of dat-1 and other mutants (Hardaway et al. 2012, 2014). Although the mutations
have not yet been mapped, the mutated genes are possible drug targets for PD (Hardaway
et al. 2012).
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The combination of genetic screening with a humanized worm model has also
been applied in PD studies. Although some human disease-contributed genes are not
conserved in C. elegans, these disease-related genes can be expressed in these worms,
and the transgenic worms can be used to study disease pathways associated with the
expressed human genes. Familial PD was first discovered in a family with α-synuclein
gene defects (Polymeropoulos et al. 1997). Although the α-synuclein gene does not have
a strong homologue present in the C. elegans genome, human α-synuclein
overexpression in worms causes dopamine neuronal death and several other phenotypes
that are characteristic of PD (Cooper et al. 2006; Lakso et al. 2003). Indeed, C. elegans
microarray studies have shown that the expression of α-synuclein causes alterations in
proteosomal and mitochondrial pathways (Vartiainen et al. 2006). Reverse genetic
screening using genome-wide RNAi techniques was employed to identify proteins
involved in human α-synuclein aggregation in worms, and 80 genes that may be involved
in PD were isolated (Van Ham et al. 2008). In a recent study, glutaredoxin was identified
as a protective protein of neurodegeneration in PD models including C. elegans (Johnson
et al. 2014). The idea of humanized worm models has also been applied in Alzheimer’s
disease by expressing human β-amyloid peptide and TAU, the major proteins of
extracellular senile plaques in Alzheimer’s disease patients (Kraemer et al. 2006;
Alexander et al. 2014; McColl et al. 2012). Thus, the overexpression strategies used in C.
elegans allow human disease pathways, as well as disease-related genes that are not
present in this organism, to be studied in this simple worm model.
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1.6.2 Chemical genetic analysis
To study disease pathways in C. elegans, chemical genetic analysis is a useful
approach that can identify molecular targets and mechanisms of already established
drugs.

For

example,

the

antidepressant

fluoxetine

regulates

serotonin

(5-

hydroxytryptamine, 5-HT) levels at the synapse cleft, however, the molecular mechanism
of this drug was not known. Therefore, C. elegans was used to study its mechanism. In C.
elegans, fluoxetine induces several behaviors including feeding, egg-laying and
locomotion, which are regulated by 5-HT (Chase and Koelle 2007). The screening of
fluoxetine-resistant mutants identified loss-of-function mutations in mod-5, which
encodes a serotonin reuptake transporter (SERT) in C. elegans (Ranganathan et al. 2001).
Further chemical genetic analysis revealed that fluoxetine could stimulate egg-laying
through the Gq protein EGL-30, suggesting that fluoxetine acts on a G-protein coupled
receptor (GPCR) signaling pathway (Dempsey et al. 2005).
Farnesyltransferase inhibitors (FTIs) block the post-translational modification of
several proteins including Ras and are known as anti-cancer compounds (Karp et al.
2001). Some FTIs have shown pro-apoptotic activity in a Ras-independent manner,
indicating the presence of additional targets. Both Ras-dependent and pro-apoptotic
phenotypes were observed in FTI-treated worms, thus, C. elegans was confirmed to be
useful in a chemical genetic study of FTIs (Lackner et al. 2005). Forward and reverse
genetic screenings have identified several endosomal trafficking proteins including the
enzyme Rab geranylgeranyl transferase (RabGGT). RabGGT was found to be
overexpressed in some tumor tissues, and its knockdown induced apoptosis in
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mammalian cancer cell lines (Lackner et al. 2005). Indeed, the chemical genetic analysis
of FTIs identified RabGGT and endosomal trafficking as potential therapeutic targets for
the modulation of apoptosis and cancers.
1.6.3 Compound screening using C. elegans
Currently, the efficiency of drug screening is of primary interest for
pharmaceuticals because the cost of drug development is rapidly increasing. During drug
screening, chemical compounds are tested in several screening steps. Hundreds of
compounds are selected from large chemical libraries during the first high-throughput
screening, which is usually performed using in vitro screening models, and those
compounds that pass the initial screening are called “hit compounds”. Then, the hit
compounds undergo the next screening processes to confirm whether they work under
more physiological conditions, often in animal models. The selected compounds after the
second screening are called “lead compounds”, which are the candidates for further drug
development (Bleicher et al. 2003). During this process, many hit compounds fail to
become lead compounds because of problems in absorption, metabolism stability, and/or
toxicity, which are found during late in vivo testing (Giacomotto and Ségalat 2010;
Gribbon and Andreas 2005). Although lead compounds may be modified to achieve a
threshold of absorption or toxicity, these modifications often reduce their drug
developability and activity (Hann et al. 2001; Oprea et al. 2001). The considerable loss of
invalid compounds from in vitro screenings results in a waste of costs and efforts. These
disadvantages can be solved directly in animal models. In addition, in vivo animal models
allow the identification of compounds that may not be obtained from in vitro cell-based
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models because such compounds only have effects on tissues and require integrated
interactions of multiple cells. Thus, the use of intact animal screening models has a much
higher possibility of obtaining physiologically active compounds. However, most animal
models show much lower throughput than in vitro cell-based screening models, and
screening large chemical libraries in such low-throughput models is time-consuming and
expensive. To overcome the limitations of traditional animal models, small animal
models including worm models have recently been spotlighted (Giacomotto and Ségalat
2010; O’Reilly et al. 2014).
The capacity of high-throughput screening applications in intact animal models
is the prominent advantage of C. elegans for compound screenings. C. elegans can absorb
chemical molecules from the intestine, skin, and sensory neuronal endings, although large
compounds may not be efficiently absorbed (Choy et al. 2006; Smith and Campbell
1996). Worms can normally be maintained in liquid buffer containing 1-2% DMSO,
which is a common solvent of chemical compounds, enabling efficient compound
exposure for screening (Nass and Hamza 2007). For high-throughput screening,
fluorescence-activated cell sorter (FACS)-like technology can be applied for worm
sorting using a Complex Object Parametric Analyzer and Sorter (COPAS) system. This
worm sorter is capable of sorting organisms ranging from 70 to 1300 µm long, thus, this
system can be applied for C. elegans and for other small organisms (Pulak 2006; Burns et
al. 2006; Boyd et al. 2012). The automated and high-speed analysis of nematodes based
on the size, OD, and intensity of fluorescent markers provides high-throughput analysis
that does not differ from in vitro cell assays. Indeed, this technology has already been
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applied in several large-scale compound screenings using C. elegans (Benson et al. 2014;
Hunt et al. 2012; Squiban et al. 2012).
1.6.4 Limitations of the C. elegans model and potential solutions
C. elegans is a powerful model for both disease pathway studies and compound
screenings. However, several limitations of this model have to be realized for proper
analysis. First, some disease pathways and molecules are simply not available in worms,
although the majority of human genes are conserved in C. elegans, and their functions
show strong correlations with human counterparts (C. elegans Sequencing Consortium
1998). Indeed, C. elegans does not have some human organs and systems, such as the
circulation system, lung, and bones. The simple body organization and relatively simple
molecular pathways of C. elegans restrict worm models to limited disease targets.
Moreover, although specific disease pathways are found in worms, they may not
completely reflect the pathology of human disease. Thus, the validation of the molecular
pathways and compounds discovered in worm models must be conducted in mammalian
models. Another major potential pitfall of worm models is that some compounds do not
work in the worm body even when the compounds are known human-optimized drugs.
To demonstrate activity, compounds must be absorbed and delivered to the right target
tissues.

A

compound’s

movement

pattern

is

called

pharmacokinetics.

The

pharmacokinetic property of a drug is not necessarily similar between humans and
worms, thus, some chemical molecules do not work or act differently in worms.
Importantly, one of the advantages of animal models is the assessment capacity of
pharmacokinetics that cannot be analyzed by in vitro models.
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Because of these drawbacks, careful preliminary studies are needed to validate
C. elegans models, particularly during the construction of compound screening models.
Results from worm studies should be always confirmed in mammalian models before
they are applied for drug studies. This validation takes advantage of high-throughput
screening in intact animals to obtain strong hit compounds during the initial screening
step.

1.7 Insulin/IGF-1-like signaling in C. elegans
Insulin/IGF-1-like signaling (IIS), which is well conserved, has been rigorously
studied in C. elegans (Fig. 1.1). The C. elegans genome contains more than 40 insulinlike peptides (ILPs) (Ritter et al. 2013) that are secreted from cells and tissues such as
neurons or intestines, respectively, and that show autocrine, paracrine, and endocrine
effects (Ritter et al. 2013; Kaletsky and Murphy 2010). Among these ILPs, some function
as agonists of DAF-2, whereas other ILPs are known to antagonize the IIS pathway. The
knockout of any single ILP or some combinations of these ILPs did not show any IIS
phenotypes, indicating that the agonistic and antagonistic effects of ILPs show
complicated redundancy rather than simple pairwise effects (Ritter et al. 2013). Many
homologues of IIS molecules have been identified and studied because of their critical
functions in the overall metabolism of C. elegans. AGE-1 was isolated as the first gene to
increase C. elegans longevity by a single gene mutation (Friedman and Johnson 1988).
The age-1 gene encodes a homologue of mammalian PI3K, which is central to the insulin
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signaling cascade in mammalian cells (Guarente and Kenyon 2000). DAF-18, a
homologue of the human tumor suppressor PTEN, suppresses AGE-1 function to
modulate IIS (Ogg and Ruvkun 1998; Liu and Chin-Sang 2014). daf-2 encodes IIS
receptor, and mutant daf-2 animals show longer lifespans (Kenyon et al. 1993). DAF-2 is
the only IR-like molecule in C. elegans, however, some splicing variants are expressed in
a tissue-specific manner (Ohno et al. 2014). Unlike mammalian IR, the DAF-2 protein
itself harbors an IRS-like domain. An independent IRS homologue IST-1, also exists,
although IST-1 is not required for the IIS pathway (Wolkow et al. 2002). AKT-1 and -2
are homologues of Akt/PKB, that activate the downstream FOXO transcription factor
DAF-16 which have shown to be indispensable for the IIS cascade in C. elegans (Paradis
and Ruvkun 1998). SGK-1, which is a homologue of mammalian serum- and
glucocorticoid-inducible kinases (SGKs), is activated by the mTORC2-like complex in C.
elegans and can phosphorylate DAF-16 similar to AKT kinases (Mizunuma et al. 2014).
pdk-1 encodes a homolog of mammalian Akt/PKB kinase PDK and functions as an
activator of AKT-1, AKT-2, and SGK-1 (Paradis et al. 1999). Finally, IIS in C. elegans is
transduced to DAF-16, a homologue of the FOXO transcription factor. DAF-16 is
normally suppressed by IIS by restricting its location to the cytoplasm. When IIS is
active, which is assumed to be the normal condition in wild-type (wt) C. elegans, DAF16 is phosphorylated by AKT-1, AKT-2, and/or SGK-1 kinases to stay in cytosolic
compartments (Wolff and Dillin 2006). This phosphorylation prevents DAF-16 from
nuclear localization and, therefore, inhibits transcription factor activity. When IIS is
inactive, this inhibition is released, and DAF-16 translocates into the nucleus to regulate
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downstream genes that cause lifespan extension and several other phenotypes. The fact
that a daf-16 mutation eliminates the knockdown phenotypes of other factors in the IIS
pathway indicates that DAF-16 is the central regulator of IIS in C. elegans (Lin et al.
2001; Murphy et al. 2003; Lee et al. 2003; Tepper et al. 2013). Thus, the molecular
pathway of C. elegans IIS represents high conservation with the mammalian insulin
signaling cascade (Haigis and Yankner 2010; Zheng and Greenway 2012). In contrast,
regulation of glucose transporters by insulin has not been reported in C. elegans. In
addition, whether IIS regulates Rac1-stimulated actin remodeling and Akt-dependent
exocytosis in C. elegans is not known. The Rac1 homologue CED-10 is found in C.
elegans and is known to regulate intracellular actin remodeling (Shakir et al. 2008),
however, no evidence of IIS regulation of this small GTPase molecule has been reported.
No homologous gene of the Akt-targeted protein AS160 is found in the C. elegans
genome. These observations imply that the insulin-induced GLUT4 translocation-type
regulation mechanism may not be conserved in C. elegans.
1.7.1 IIS phenotypes
IIS activity is known to be required for many biological processes in C. elegans.
A long lifespan is a signature phenotype of IIS mutants. The relatively short lifespan of
C. elegans is a considerable advantage for studies regarding longevity regulatory
pathways including IIS (McCormick et al. 2012; Kenyon et al. 1993). DAF-16 is a
known central regulator of the aging processes in C. elegans. DAF-16 activation by IIS or
by other pathways leads to increased oxidative stress responses and autophagy activity,
which are thought to be the major factors of lifespan extension (Munkácsy and Rea
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2014). Oxidative stress is assumed to have central roles in aging and is closely related to
mitochondrial activity. daf-2 mutants have decreased intracellular glucose levels (Schulz
et al. 2007). Under cellular glucose-deficient conditions, mitochondrial activity is upregulated to counteract energy depletion, and the activated mitochondria produce
additional reactive oxygen species (ROS), which are harmful to cells (Schulz et al. 2007).
However, induced ROS activate several oxidative stress response genes that protect cells
from ROS damage (Zarse et al. 2012; Schulz et al. 2007; Cypser et al. 2006). In daf-2
mutants, the oxidative stress response increases, which positively affect longevity.
IIS also regulates reproductive ability and timing. The DAF-2 mutant shows a
significantly decreased progeny number, which is thought to be caused by a defect in
oocyte production (Gems et al. 1998). IIS is required for germline proliferation, which is
critical for the complete development of gonads and the production of gametes
(Michaelson et al. 2010). Interestingly, germline proliferation defects are not observed in
adult-stage DAF-2 mutants, and other signaling cascades, such as Notch signaling,
regulate germ cell differentiation throughout the adult stage (Austin and Kimble 1987).
IIS mutants show increased fat storage (Kimura et al. 1997; Horikawa and
Sakamoto 2010). DAF-16 activates the expression of genes associated with lipid
accumulation, such as fatty acid desaturase FAT-2, -6, and -7 and fatty acid elongase
ELO-2 (Ashrafi et al. 2003; Horikawa and Sakamoto 2010). RNAi of these genes caused
reduced fat accumulation because of the up-regulation of β-oxidation-related genes
(Horikawa et al. 2008; Van Gilst et al. 2005). Thus, IIS mediates the activation of lipid
synthesis and the inactivation of β-oxidation, leading to fat accumulation in IIS mutant
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animals. In addition, fat accumulation phenotypes are observed in many dauer pathway
mutants (Watts 2009). Because dauer larvae live an extremely long period without
feeding, they require more fat storage to keep the energy supply from fatty acid βoxidation and gluconeogenesis. Indeed, unlike mammals, C. elegans possesses a
glyoxylate pathway, which converts acetyl-CoA into oxaloacetate to efficiently utilize
oxidized fatty acids for gluconeogenesis (Fig. 1.2) (McElwee et al. 2006). Importantly,
the glyoxylate cycle may be up-regulated in daf-2 mutants (Depuydt et al. 2014).
1.7.2 Energy metabolism in C. elegans
Similar to other animals, glucose is an important energy source in C. elegans
(Braeckman et al. 2009; Lu and Goetsch 1993). Environmental glucose availability
affects cellular energy metabolism, which causes changes in several phenotypes in C.
elegans. Glucose supplementation in culture medium alters reproduction, dauer formation,
growth, and lifespan phenotypes, which are well known to be dependent on IIS
(Mondoux et al. 2011; Schlotterer et al. 2009; Choi 2011; Lee et al. 2009). For instance,
0.1-2% of glucose supplementation decreases lifespan of wt worms and eliminates the
extended lifespan of daf-2 mutant strains (Lee et al. 2009; Schlotterer et al. 2009; Schulz
et al. 2007). The glucose effect is specific to D-glucose, but not to L-glucose, indicating
that the phenotype change is due to glucose metabolism because L-glucose is a nonmetabolized enantiomer of glucose in C. elegans (Lee et al. 2009). In addition to glucose,
glycerol production is also thought to have an important function in the aging process.
Dietary glycerol can also decrease the lifespan of these worms. These dietary glucose and
glycerol effects are dependent on the activity of AQP-1, a glycerol transporter protein
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(Lee et al. 2009), implying that gluconeogenesis from glycerol may be an important
source of glucose in C. elegans. Moreover, trehalose, a disaccharide form of glucose,
may be important for glucose storage in C. elegans (Pellerone et al. 2003). Interestingly,
supplementation with trehalose can increase the lifespan of C. elegans, although trehalose
can be directly metabolized to produce glucose in these worms (Honda et al. 2010). Since
trehalose itself has other physiological functions such as cell defense in dauer larvae
(Erkut et al. 2011), the trehalose-induced lifespan extension may result from its functions
beyond energy metabolism.
Transcriptomic, proteomic, and metabolomic studies have shown overwhelming
metabolic shifts in IIS mutants, such as daf-2 mutants. In energy metabolism, enzymes in
glycolysis, gluconeogenesis, and the TCA cycle, including glyoxylate shunt enzymes, are
thought to be up-regulated in daf-2 mutants (Fuchs et al. 2010; Depuydt et al. 2014). In
addition, the intracellular concentrations of several metabolites that are intermediate
products of glucose metabolism cascades show significant changes in daf-2 mutants
(Fuchs et al. 2010; Depuydt et al. 2014). Elevated metabolite availability is thought to be
one of the critical factors of the longer lifespan of IIS mutants because other long-lived
strains share similar metabolite profiles (Fuchs et al. 2010; Depuydt et al. 2014).
Furthermore, sugar uptake activity is significantly decreased in daf-2 mutants (Zarse et al.
2012; Feng et al. 2013), although the intracellular glucose concentration is similar in daf2 mutants compared to wt (Fuchs et al. 2010). All of these observations indicate that
energy metabolism in C. elegans is tightly regulated by IIS as in mammals.
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1.8 Conclusion and the aims of this study
Understanding glucose homeostasis regulation is crucial for the development of
medications to treat metabolic diseases including diabetes. Although the maintenance of
glucose homeostasis involves various regulatory mechanisms, the regulation of glucose
transporters is a critical mechanism. C. elegans has emerged as an ideal model system for
studying the mechanisms by which insulin regulates glucose transporters because of its
unique advantages and the conservation of the IIS pathway. The overwhelming evidence
that energy metabolism is tightly regulated by IIS in C. elegans supports our hypothesis
that glucose transporter function is regulated by IIS in this organism.
Thus, the objective of this study is to investigate whether and how IIS regulates
glucose transporters in C. elegans. Our specific aims are as follows: i) to identify
facilitative glucose transporters in C. elegans (FGTs), ii) to study whether the
functions of FGTs are regulated by IIS, and iii) to investigate how IIS regulates
FGTs. Our study will establish C. elegans as a powerful model to study the mechanism
by which insulin regulates glucose transport and provide insights into the mechanism of
defective glucose uptake by tissues in diabetes patients.
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1.9 Table and Figures
Table 1.1. Summary of the human sugar transporter families
Human gene Protein
Predominant substrates
Facilitative glucose transporter family (GLUT)
SLC2A1
GLUT1
Glucose, galactose, mannose, glucosamine
SLC2A2
GLUT2
Glucose, galactose, fructose, mannose, glucosamine
SLC2A3
GLUT3
Glucose, galactose, mannose, xylose
SLC2A4
GLUT4
Glucose, glucosamine
SLC2A5
GLUT5
Fructose
SLC2A6
GLUT6
Glucose
SLC2A7
GLUT7
Glucose, fructose
SLC2A8
GLUT8
Glucose, fructose, galactose
SLC2A9
GLUT9
Urate, glucose, fructose
SLC2A10
GLUT10
Glucose, galactose
SLC2A11
GLUT11
Glucose, fructose
SLC2A12
GLUT12
Glucose
SLC2A13
GLUT13/HMIT myo-inositol
SLC2A14
GLUT14
Sodium-coupled glucose transporter family (SGLT)
SLC5A1
SGLT1
Glucose, galactose
SLC5A2
SGLT2
Glucose
SLC5A3
SGLT3
Sensing of glucose
SWEET family
SLC50A1
SWEET1
Glucose

Tissue distribution
Ubiquitous distribution
Liver, islets, kidney, intestine, brain
Brain, neurons, testis, leucocytes
Muscle, heart, fat
Intestine, kidney
Brain spleen, leucocytes
Intestine, colon, testis, prostate
Testis, blastocyst, brain, musle, adipocytes
Kidney, liver, intestine
Heart, musle, liver, pancreas
Heart, muscle
Heart, prostate, mammary gland
Brain, fat
Testis
Kidney, intestine
Kidney, intestine
Intestine, skeletal muscle
Golgi apparatus

SLC: solute carrier gene super family, References: Modified tables from Zhao and Keating 2007, Mueckler and Thorens 2013
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Human

C. elegans
Insulin
IR

Insulin-like peptides
DAF-2
IRS-like domain on DAF-2,
IST-1

IRSs
Rac1

PI3K

?
CED-10

AGE-1

PTEN

DAF-18

PDK-1

PDK1,2

mTORC2-like
complex

mTORC2

?

GLUT4
translocation

AS160

SGK-1

AKT-1,-2

AKT1,2

?
FOXO1

DAF-16

Glucose transporter
translocation?

Figure 1.1. Conservation of insulin signaling molecules between humans and
Caenorhabditis elegans
Insulin signaling molecules and signaling cascades in humans and Caenorhabditis
elegans (C. elegans) are shown. Activation is indicated with arrow-headed lines, and
inhibition is indicated with bar-headed lines. Unknown regulatory mechanisms are
indicated with a dashed line with a question mark. The double line indicates the plasma
membrane of the cell.
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Glycolysis
β-oxidation

Gluconeogenesis

Citrate
Isocitrate

Oxaloacetate
Acetyl-CoA

CO2
Malate

Glyoxylate

α-ketoglutarate

CO2
Succinyl-CoA

Fumarate

Succinate

Figure 1.2. Overview of the glyoxylate cycle
Substrates in tricarboxylic acid (TCA) cycle and glyoxylate cycle are shown. Glyoxylate
cycle specific reactions are indicated by arrow-headed red lines. TCA cycle specific
substrates and reactions are indicated with gray color.
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2.1 Abstract
Caenorhabditis elegans (C. elegans) is an attractive animal model for biological and
biomedical research because it permits relatively easy genetic dissection of cellular
pathways, including insulin/IGF-like signaling (IIS), that are conserved in mammalian
cells. To explore C. elegans as a model system to study regulation of the facilitative
glucose transporter (GLUT), we have characterized the GLUT gene homologues in C.
elegans: fgt-1, R09B5.11, C35A11.4, F53H8.3, F48E3.2, F13B12.2, Y61A9LA.1,
K08F9.1 and Y37A1A.3. Exogenous expression of these gene products in Xenopus oocyte
showed transport activity to unmetabolized glucose analogue 2-deoxy-D-glucose only in
FGT-1. The FGT-1 mediated transport activity was inhibited by the GLUT inhibitor
phloretin and exhibited a Michaelis constant (Km) of 2.8 mM. Mannose, galactose and
fructose were able to inhibit FGT-1 mediated 2-deoxy-D-glucose uptake (P < 0.01),
indicating that FGT-1 is also able to transport these hexose sugars. A GFP fusion protein
of FGT-1 was seen only on the basolateral membrane of digestive tract epithelia in C.
elegans, but not in other tissues. FGT-1::eGFP expression was seen from early embryonic
stages. Knockdown or mutation of fgt-1 resulted in increased fat staining in both wildtype and daf-2 (mammalian insulin receptor homologue) mutant animals. Other known
common phenotypes of IIS mutant animals, including dauer formation and brood size
reduction, were not affected by fgt-1 knockdown in wild-type or daf-2 mutants. Our
results indicated that in C. elegans, FGT-1 is mainly a mammalian GLUT2-like intestinal
glucose transporter and is involved in lipid metabolism.
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2.2 Introduction
Glucose is an essential energy source and substrate for macromolecule synthesis in
most, if not all, living organisms. In mammalian cells, glucose is taken up by two
families of glucose transporters located in the cell plasma membrane. The facilitated
glucose transporters (GLUT, gene symbol: SLC2A) mediate passive glucose diffusion
across the plasma membrane in most tissues while Na+/glucose cotransporters (SGLT,
gene symbol: SLC5A) mediate Na+-dependent secondary active glucose transport mainly
in the epithelial cells of the small intestine and kidney convoluted tubules [1,2].
The GLUT family contains 14 members which have high sequence similarities and
share common structure characteristics, including 12 transmembrane domains and sugar
transporter signatures [2,3]. However, individual transporters have different transport
kinetics, tissue distribution and regulatory properties [2]. Among the 14 members, class I
GLUTs

(GLUT1-4)

are

well

studied

because

of

their

physiological

and

pathophysiological roles in the cells. GLUT1 is ubiquitously expressed and mediates
basic glucose uptake. GLUT2 is mainly localized in the plasma membrane of hepatic
cells and the basolateral membrane of the luminal epithelial cells of the intestine and
kidney convoluted tubules [4]. In intestinal and kidney cells, GLUT2 is responsible for
releasing glucose absorbed or reabsorbed by SGLT1 or SGLT2 in the apical membrane
into the blood stream [2,5,6]. GLUT3 is known as a neuron-specific glucose transporter
and is mainly expressed in the brain [7,8]. GLUT4 mediates insulin-regulated glucose
uptake in muscle cells and adipocytes. In these cells, insulin stimulates translocation of
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GLUT4 from the intracellular pool to the plasma membrane and thus, increases glucose
uptake and utilization [9,10]. This regulation plays a critical role in maintaining whole
body glucose homeostasis. GLUTs belong to the major facilitator superfamily (MFS)
consisting of members present ubiquitously in bacteria, archaea, cyanobacteria, fungi,
protozoa, plants and animals.
C. elegans is an attractive animal model for biological and biomedical research
because of its small size, simplicity, short lifespan (21 days) and quick turn over (3 days),
ease of propagation and maintenance, routine genetic manipulations, and costeffectiveness. It has been widely used as a model system for studying aging, reproduction,
metabolism, and other physiological processes that are well known to be regulated by
insulin/IGF-like signaling (IIS). IIS is well conserved in C. elegans and many
mammalian insulin signaling molecule homologues have been identified (e.g., DAF-2 is
the C. elegans counterpart of mammalian insulin receptor) and studied in C. elegans.
However, there have been no GLUT homologues functionally identified in C. elegans
and no studies have been published in IIS regulation of glucose uptake in C. elegans so
far.
To explore C. elegans as a model system to study regulation of glucose transporter
functions, especially by IIS, we have characterized potential C. elegans GLUT
homologues, fgt-1, R09B5.11, C35A11.4, F53H8.3, F48E3.2, F13B12.2, Y61A9LA.1,
K08F9.1 and Y37A1A.3, which show high sequence homologies to human GLUTs.
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2.3 Results
2.3.1 Bioinformatic analysis of GLUT homologues in C. elegans genome
BLASTP searches were performed using protein sequences of human GLUT1
through

12

genes

against

the

C.

elegans

database

(Wormbase:

http://www.wormbase.org/). 47 genes were found to have higher scores than a cut off Evalue of 1E-2 (Table S2.1). After removing those candidates with known functions other
than sugar transport, the remaining candidates were analyzed for facilitative glucose
transporter signatures, including 12 transmembrane domains [3], a N-glycosylation site
either within the first or sixth extracellular loop and several highly conserved residues [2].
Nine genes, including fgt-1, R09B5.11, C35A11.4, F53H8.3, F48E3.2, F13B12.2,
Y61A9LA.1, K08F9.1, and Y37A1A.3, passed these analyses and are considered initial C.
elegans GLUT (ceGLUT) candidates (Figure 2.1). FGT-1 and R09B5.11 have the highest
homologies to the class I family of human GLUTs (hGLUTs) compared to the other
candidates. The BLASTP E-values of FGT-1 and R09B5.11 against hGLUT1 or
hGLUT4 were 7E-82, 1E-66, 3E-84 and 6E-67, respectively, which were much lower
than other candidates (> 2E-36 and > 5E-31 to hGLUT1 and hGLUT4, respectively)
(Table S2.1). R09B5.11 was predicted to lack two potential transmembrane domains
(Figure 2.1) but remained in the candidate list because of its high E-values in our
BLASTP analysis.
The deduced amino acid sequences of all 9 ceGLUT candidates were aligned with the
class I family of hGLUTs in Figure S2.1. Figure 2.2A shows the higher resolution

63

alignments of FGT-1 and R09B5.11 with hGLUT1-4. These alignments showed that
many residues were well conserved in these sequences, including those in transmembrane
domain (TM) 1 and 5 which were predicted to be absent in R09B5.11 and some residues
that are known to be functionally important in hGLUTs, such as R92, E146, R153, E329,
R333/4, W388, E393, R400, and W412 as reported by Schurmann et al. (2007) [11].
Moreover, they all contained deduced sugar transporter domains and major facilitator
domains (PFAM: http://pfam.sanger.ac.uk/). A phylogenetic tree drawn by the alignment
showed that hGLUT2 was the closest isoform for all ceGLUT candidates and FGT-1 and
R09B5.11 were the closest homologues to human class I GLUTs (Figures 2.2B and S2.2).
Thus, we pursued functional characterizations of all of these 9 ceGLUT candidates.
We first cloned the full length cDNAs of these C. elegans genes by PCR using specific
primers which are located in 5’- or 3’-untranslated regions of corresponding genes based
on the sequence information in Wormbase. In the database, fgt-1 was predicted to have
two mRNA variants, fgt-1a and fgt-1b, which are different in the first exon, resulting in
different N-termini of the protein. We cloned fgt-1a cDNA for this study because the fgt1a showed a slightly lower E-value than fgt-1b in our BLASTP search against class I
family of hGLUTs (Table S2.1).

2.3.2 Glucose transport activity of ceGLUT candidates
The functional glucose transport activities of ceGLUT candidates were assessed in
Xenopus laevis oocytes. Synthesized cRNA of individual ceGLUT candidates was
injected into oocytes and the oocytes were then incubated in 10 mM 2-deoxy-D-glucose
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(2-DG) containing 1 μCi 2-deoxy-D-[1-3H]-glucose (3H-2-DG) for 15 min. The hGLUT1
cRNA-injected oocytes were used as a positive control and the water-injected oocytes
were used to determine the endogenous levels of glucose uptake in the oocytes. FGT-1
showed significant 2-DG transport activity although the activity appeared much lower
than hGLUT1, while all other gene products examined showed no activity for 2-DG
transport (Figure 2.3A). We confirmed the plasma membrane localizations of FGT-1 and
R09B5.11 in the oocytes by injection of GFP fusion constructs of FGT-1 and R09B5.11
into oocytes. Both FGT-1::eGFP and R09B5.11::eGFP were localized in the plasma
membrane of oocytes (Figure 2.3B, C). The eGFP fusion protein of FGT-1 showed the
same 2-DG uptake activity as non-fusion FGT-1 while R09B5.11::eGFP fusion protein
failed to show activity, similar to our results for untagged R09B5.11 (Figure 2.3D). These
results indicated that although the R09B5.11 is localized to the plasma membrane, it has
no transport activity to glucose, unlike FGT-1.
Since facilitative glucose transport is known to be inhibited by phloretin, we
examined if the glucose transport activity of FGT-1 is inhibited by phloretin. The fgt-1
cRNA-injected oocytes were incubated in 2-DG solution including increasing
concentrations of phloretin from 0 μM to 200 μM. Phloretin significantly inhibited FGT1 mediated 2-DG uptake with concentration of 50 μM or higher (P < 0.01, n = 10)
(Figure 2.3E). Non-linear one phase decay analysis estimated an inhibitory plateau at 277
pmols/oocyte/15min.
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We further performed the transport kinetic analysis of FGT-1 to 2-DG with increasing
concentrations of 2-DG (Figure 2.3F). The Km value of FGT-1 for 2-DG was determined
to be 2.8 mM.

2.3.3 Hexose substrate specificity of FGT-1
The substrate specificity of FGT-1 to different hexose sugars was analyzed by the
competitive inhibition of mannose, galactose and fructose, on 2-DG uptake of FGT-1 in
oocytes (Figure 2.4). The inhibition effects of hexose sugars were compared with that of
L-glucose, which is not transported by GLUTs [12]. Indeed, L-glucose showed no
inhibition to the 2-DG uptake by FGT-1 as compared to the uptake without addition of
any hexose sugar (Figure 2.4). The 2-DG uptake by FGT-1 was significantly inhibited by
D-glucose (79 % inhibition), 3-O-methylglucose (77 %), D-mannose (79 %), D-galactose
(33 %) or D-fructose (42 %) (P < 0.01, n = 40, Figure 2.4). These results indicated that
FGT-1 is able to transport D-mannose as well as D-glucose and is also able to transport
D-fructose and D-galactose with lower activities.

2.3.4 Cellular and subcellular localizations of FGT-1 and R09B5.11 in C. elegans
To study the specific physiological functions of FGT-1, we built the fgt-1::egfp
fusion construct under the control of 2 kb upstream promoter sequences of fgt-1. The
plasmid was injected into C. elegans. The expression of FGT-1::eGFP fusion protein was
observed in pharyngeal muscle and intestinal cells (Figure 2.5A). The expression started
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from early embryonic stage (Figure 2.5B). In adult animals, FGT-1::eGFP was mainly
localized in the plasma membrane of intestinal cells (Figure 2.5C). To determine the
apico-basal polarity of FGT-1::eGFP subcellular localization, we immunostained the fgt1::egfp animal embryos with an antibody to the apical membrane marker IFB-2 which is
an intermediate filament protein and a component of the terminal web on the apical
domain of intestinal cells [13,14]. FGT-1::eGFP was not co-localized with IFB-2,
suggesting that FGT-1::eGFP was only expressed on the basolateral membrane but not on
the apical membrane (Figure 2.5D-I). In addition, FGT-1::eGFP localization was not
affected by fasting (data not shown).
Expression of R09B5.11::eGFP was also observed in C. elegans. R09B5.11::eGFP
was expressed from the early embryonic stage through the L2 stage and appeared to be
expressed in seam cells (Figure 2.6).

2.3.5 In vivo functional analysis of FGT-1 in C. elegans
Because FGT-1 is mainly located in intestinal cells, which are the major site of fat
accumulation in C. elegans, we studied the role of fgt-1 in fat accumulation. We injected
into C. elegans 112 bp double stranded fgt-1 RNA (dsRNA) synthesized from exon 6 of
the fgt-1 gene, which has limited sequence homologies to other GLUT homologues. The
fgt-1 mRNA levels measured by real-time RT-PCR did not show a significant reduction
of fgt-1 mRNA in the C. elegans injected with fgt-1 dsRNA (data not shown). Due to the
lack of the antibodies to FGT-1, we confirmed the RNAi effect on fgt-1 protein levels by
injecting fgt-1 dsRNA into fgt-1::egfp transgenic animals. F1 progeny were analyzed by
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Western blotting analysis using an anti-GFP antibody. In dsRNA-injected transgenic
animals, FGT-1::eGFP protein level was decreased to 16% of that in the animals injected
with buffer, confirming the knockdown effect of our RNAi (Figure 2.7A, B).
The fgt-1 dsRNA was then injected into wild-type and daf-2 mutant animals and fat
was then stained in these animals with sudan black B. As shown in Figure 2.7C and 2.7D,
fat staining intensity in the wild-type and daf-2 mutant C. elegans injected with fgt-1
RNAi was 139% and 109%, respectively, compared to the control animals (P < 0.001, n
> 47). We further confirmed this result in a fgt-1(tm3165) mutant animal which showed
9% higher fat storage compared to wild-type animals (P < 0.01, n = 41) (Figure 2.7E).
In addition, we analyzed the effects of fgt-1 RNAi on dauer formation and brood size.
For both phenotypes, fgt-1 RNAi had no significant effect in wild-type and daf-2(e1370)
animals (Figure 2.7F, G). Increasing cultivation temperature to 25 °C from 20 °C, which
led to strong dauer formation in daf-2(e1370), also had no effects on dauer formation by
fgt-1 RNAi in both wild-type or daf-2(e1370) animals (Figure 2.7F).

2.4 Discussion
BLASTP searches of C. elegans genome with hGLUT cDNAs and structural
analyses resulted in nine C. elegans GLUT candidate genes: fgt-1, R09B5.11, C35A11.4,
F53H8.3, F48E3.2, F13B12.2, Y61A9LA.1, K08F9.1, and Y37A1A.3. Among them, fgt-1
and R09B5.11 displayed the highest sequence homologies to the class I family of
hGLUTs. Thus, in this study, we aimed to characterize the glucose transport properties of
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these proteins and study their physiological functions in C. elegans. The glucose transport
properties of all 9 ceGLUT candidates were first assayed in Xenopus oocyte model,
which is broadly used for measurement of glucose transporter activity because of its very
low endogenous glucose transport level [15]. While FGT-1 showed significant glucose
transport activity, no such activity was observed for all of other candidates. Since
R09B5.11 was localized on the plasma membrane in oocytes, our results indicated that
unlike FGT-1, R09B5.11 is not a facilitative glucose transporter in C. elegans. The
inability of R09B5.11 to transport glucose may be explained by its structural analysis.
Although it has high sequence homologies to GLUTs and FGT-1 (55 % to hGLUT1 and
62% to FGT-1), it is predicted to have only 10 TMs rather than 12 TMs predicted in all
hGLUTs [2,3] and FGT-1. R09B5.11 may lack one or two TMs that are required for
glucose transport function or all 12 TMs may be essential [3]. However, R09B5.11
showed expression in the early developmental stage and may play a role in development.
Although it had no transport activity for glucose, it may have transport activity to other
substrates. Similar to R09B5.11, all other 7 candidates showed no transport activity to
glucose, however, we cannot completely exclude the possibility that these proteins
transport glucose because we have not examined their subcellular localizations. If a
protein is localized intracellularly in our experimental condition, its transport activity
would not be revealed in our analysis.
Since FGT-1 showed glucose transport activity, we further analyzed its transport
properties and kinetics. The transport activity of FGT-1 can be inhibited by a facilitative
glucose transport inhibitor phloretin [16] in a dose dependent manner. Kinetic assays
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revealed that FGT-1 has a Km of 2.8 mM for 2-DG, an un-metabolized glucose analog.
This Km value is much lower than the Km reported for hGLUT1 (11.7 mM) or hGLUT4
(4.6 mM) [17,18], which is not surprising because C. elegans lives in a low glucose soil
environment and may require cells to have transporters with a high affinity for glucose
for its acquisition. In addition, we showed that the 2-DG transport activity of FGT-1 can
be inhibited by not only D-glucose and glucose analogs 3-OMG, but also by several other
hexose sugars, including D-mannose, D-galactose and D-fructose. It appears that FGT-1
can transport D-mannose equally well as D-glucose, but has relative low activities for Dfructose and D-galactose.
To study the in vivo physiological functions of FGT-1 in C. elegans, we first
investigated its cellular and subcellular localizations in whole animals using FGT1::eGFP fusion protein controlled by the fgt-1 promoter. Since the eGFP fusion protein of
FGT-1 showed the same 2-DG uptake activity as non-fusion FGT-1 in our oocyte assay,
FGT-1::eGFP should reflect FGT-1 native localization in C. elegans, although
experiments to determine if FGT-1::eGFP can functionally rescue fgt-1 mutant
phenotypes are needed to fully support this conclusion. FGT-1 is seen to be mainly
distributed to the basolateral membrane of intestinal cells. In mammals, intestinal glucose
absorption is mainly mediated by the Na+/glucose cotransporter SGLT1 located on the
apical membrane [19]. It is not known whether C. elegans uses the same mechanism and
a SGLT1 homologue has not been reported in C. elegans. A BLASTP search using
human SGLT sequences showed no SGLT homologous genes in C. elegans. Nevertheless,
it is likely that glucose is also absorbed from the intestine lumen by an active glucose
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transporter in C. elegans. FGT-1 may play a role similar to mammalian GLUT2 which is
responsible for releasing absorbed glucose from the intestinal cells to interstitial fluid
[2,5,6]. Supporting this idea, our phylogenetic tree analysis indicates that hGLUT2 is the
closest human class I GLUT isoform to FGT-1.
We next investigated the effects of knockdown of fgt-1 on multiple physiological
phenotypes in C. elegans. We found that fat staining was increased in fgt-1 knockdown
and mutant worms. This is consistent with our observation that FGT-1 is an intestinal
transporter because intestine is the major site of lipid storage in C. elegans [20,21]. This
result also suggests a role for FGT-1 in lipid metabolism in C. elegans. However, it is
surprising that knockdown or mutation of fgt-1 resulted in an increased fat staining
because it indicates that knockdown or mutation of fgt-1 results in either an increased
lipogenesis or a decreased lipolysis or a combination of both. Since glucose is a substrate
and an energy source for lipid synthesis, increased fat staining in fgt-1 knockdown and
mutant animals implies that glucose is not limited in these cells. This is consistent with
our hypothesis that FGT-1 may be involved in release of absorbed glucose from intestinal
cells, not in glucose absorption. Malfunctions of FGT-1 may reduce glucose release and
increase intracellular glucose levels in intestinal cells, leading to increased lipid synthesis.
We did not observe any effects of knockdown of fgt-1 on dauer formation and brood
size, indicating that FGT-1 does not play an essential role in overall energy metabolism
and reproductive function in C. elegans. C. elegans undergoes dauer larva formation
when nutrients become limited [22]. Thus, knockdown of fgt-1 appears not to have a
detrimental effect on energy metabolism in C. elegans, which is also consistent with our
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observation that FGT-1 is local to intestine cells and may not be responsible for glucose
uptake in other tissues and cells in C. elegans. Other glucose transporter isoforms may
have to be expressed in other tissues and cells to mediate glucose uptake. Another
explanation is that C. elegans cells may be able to efficiently use other energy sources to
replace glucose, such as glycerol [23].
It is well studied that insulin stimulates GLUT4 translocation in mammalian adipose
cells and muscle cells [9,10]. During fasting, GLUT4 is mainly located intracellularly
while after feeding, the rising insulin levels in blood stimulate GLUT4 translocation to
the plasma membrane which increases glucose uptake by the cells. We investigated the
possibility that IIS may regulate FGT-1 subcellular localization in C. elegans by
examining the subcellular location of FGT-1::eGFP in fasting condition. The localization
of the fusion protein showed no changes compared to non-fasting condition. In addition,
since dauer formation and reproduction as well as fat staining are well known to be
regulated by IIS in C. elegans and none of them were affected by the knockdown of
FGT-1 in both wt and daf-2 mutant in this study, our data suggest that FGT-1 may not be
involved in IIS regulation of these processes. However, our data in daf-2(e1370) was
confounded by the non-null nature of the allele. Further studies with different IIS
signaling mutant, such as daf-16 (a mammalian FOXO homologue), and with different
culture conditions (such as temperature and calorie restriction) are required to make this
conclusion.
In summary, in this study we have identified FGT-1 as a mammalian GLUT
counterpart in C. elegans. FGT-1 is a digestive tract specific isoform located in the
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basolateral membrane of intestinal epithelial cells. Thus, FGT-1 may function like
mammalian GLUT2 and serve to release glucose from intestinal cells to the interstitial
fluid. Knockdown or mutation of fgt-1 increases fat storage in intestinal cells, indicating a
role of FGT-1 in lipid metabolism in C. elegans.

2.5 Materials and Methods
2.5.1 C. elegans strains and culture
C. elegans strains used in this study were obtained from the Caenorhabditis Genetics
Center (http://www.cbs.umn.edu/cgc). The strains used were wild-type N2 and daf2(e1370). C. elegans strains were cultivated at 20 °C under standard conditions [24].

2.5.2 Plasmid constructions
PCR primers used for all plasmid constructions are listed in Table 2.1. PCR reactions
in plasmid constructions were all carried out using the high fidelity Platinum Pfx DNA
polymerase (Invitrogen) unless otherwise specified. The full length cDNA of individual
genes was amplified from the cDNA library of wild-type worms with the following
primer sets: fgt1-5utr and fgt1-3utr for fgt-1, R09-5utr and R09-3utr for R09B5.11, C355utr and C35-3utr for C35A11.4, F53-5utr and F53-3utr for F53H8.3, F48-5utr and f483utr for F48E3.2, F13-5utr and F13-3utr for F13B12.2, Y61-5utr and Y61-3utr for
Y61A9LA.1, K08-5utr and K08-3utr for K08F9.1 and Y37-5utr and Y37-3utr for
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Y37A1A.3. The cDNA amplicons were inserted into the pCR-blunt II-TOPO vector
(Invitrogen) to form pCR-fgt1, pCR-R09, pCR-C35, pCR-F53, pCR-F48, pCR-F13,
pCR-Y61, pCR-K08, and pCR-Y37 plasmids, respectively.
C. elegans expression plasmids of fgt-1 and R09B5.11 were constructed in C.
elegans expression vectors pPD95.77 and pPD95.79 (Addgene plasmids 1495 and 1496)
which harbor eGFP gene for expressing FGT-1::eGFP or R09B5.11::eGFP fusion
proteins. A 2 kb promoter sequence upstream of the transcription initiation site of each
gene was also cloned to the vectors to direct fusion gene expression. The fgt-1 promoter
was amplified from C. elegans genomic DNA with the primer set of fgt1up-5sph and
fgt1up-3, and the fgt-1a full length cDNA was amplified from the pCR-fgt1 plasmid with
the primer set of fgt1cdna-5 and fgt1cdna-3xba. Both amplicons were digested with Sph I
and Xba I, respectively, and ligated simultaneously into Sph I- and Xba I-digested
pPD95.77 to form the C. elegans expression plasmid of fgt-1 (pPD-fgt1g). The R09B5.11
promoter sequence was amplified from the C. elegans genomic DNA with the primer set
of R09up-5sph and R09up-3, and the full length cDNA sequence was amplified from the
pCR-R09 plasmid with the primer set of R09-5utr and R09cdna-3sma. These amplicons
were used as the templates for overlap extension PCR amplification of the DNA fragment
containing both the promoter and cDNA by the primer set of R09up-5sph and R09cdna3sma. This amplicon and the pPD95.79 vector were digested with Sph I and Sma I, and
then ligated to form the C. elegans expression plasmid of R09B5.11 (pPD-R09g).
To construct the Xenopus oocyte expression plasmid of individual genes, the full
length cDNA of each gene was respectively inserted into the pSP64T vector, a plasmid
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which contains 5’- and 3’-flanking sequences of Xenopus β-globin gene [25]. The fgt-1
cDNA was excised from pCR-fgt1 plasmid with Kpn I and Xho I. The R09B5.11,
F48E3.2, and Y37A1A.3 cDNAs were excised from the pCR-R09, pCR-F48, and pCRY37 plasmid by EcoR I, respectively. The C35A11.4, F13B12.2 and Y61A9LA.1 cDNAs
were excised from pCR-C35, pCR-F13 and pCR-Y61 plasmids with Sac I and Pst I,
respectively. The F53H8.3 and K08F9.1 cDNAs were excised from pCR-F53 and pCRK08 plasmids with Kpn I and Pst I, respectively. The pSP64T vector was digested with
Bgl II. These digested vector and individual cDNAs were blunted by T4 DNA
polymerase (New England Biolabs) and then individually blunt-ligated to form the
expression plasmids of fgt-1 (pSP-fgt1), R09B5.11 (pSP-R09), C35A11.4 (pSP-C35),
F53H8.3 (pSP-F53), F48E3.2 (pSP-F48), F13B12.2 (pSP-F13), Y61A9LA.1 (pSP-Y61),
K08F9.1 (pSP-K08) and Y37A1A.3 (pSP-Y37), respectively. The human GLUT1 plasmid
in pSP64T, pSP64T-hGLUT1, was a generous gift from Gwyn Gould [25].
To observe fgt-1 and R09B5.11 subcellular localizations in Xenopus oocytes, the fgt1::egfp and R09B5.11::egfp fragments were also inserted into the pSP64T vector. These
fragments were cloned from fgt-1::egfp or R09B5.11::egfp transgene-expressed worms
by PCR with the primer set of fgt1g-5bcl and ppd-3bcl or R09g-5bgl and ppd-3bgl,
respectively. The amplified fgt-1::egfp fragment was digested with Bcl I and
R09B5.11::egfp fragment was digested with Bgl II. These fragments were then ligated
into the Bgl II-digested pSP64T vector to form pSP-fgt1g and pSP-R09g.
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2.5.3 Generation of transgenic worms
Transgenic worms were generated as described previously [26]. The rol-6d pRF4
(generous gift of M. Koelle, Yale University) was used as a coinjection marker [27,28].
pPD-fgt1g plasmid was microinjected into the wild-type animals with pRF4 at 100 μg/ml.
Animals were then fixed with 10 mM sodium azide. Transgenic animals bearing the gfp
reporter were selected by the roller phenotype and observed under a confocal laser
microscopy (Zeiss LSM 510 META Laser Scanning Microscope).

2.5.4 Xenopus oocyte harvest and injection of cRNA into oocytes
cRNAs of fgt-1, R09B5.11 and hGLUT1 were synthesized by in vitro transcription
from the pSP-fgt1, pSP-R09 and pSP64T-hGLUT1, respectively, using the mMessage
mMachine kit (Ambion). Oocytes were harvested from Xenopus laevis. The synthesized
cRNA (2 μg/μL) or sterile water was injected into isolated mature oocytes (stage V and
VI) following previously established procedures [17].
The use of Xenopus laevis in this study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional Animal Care
and Use Committee of the University of Vermont (#13-025).
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2.5.5 Glucose uptake, kinetic and inhibition assays
2-DG uptake and its kinetic and inhibition analyses of FGT-1 and R09B5.11 were
carried out in Xenopus oocytes as described previously [17]. cRNA- or water-injected
oocytes were incubated in Barth’s media [88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3,
0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 mM Ca(NO3)2, 5 mM HEPES, pH 7.6] with 10
μg/mL penicillin and 10 IU/mL streptomycin (Gibco) for three days and then subjected
for uptake assay using 10 mM 2-DG containing 1 μCi 3H-2-DG. For phloretin inhibition
assay, 0, 10, 25, 50, 75, 100 or 200 μM of phloretin were added to the assays,
respectively. For substrate specificity assay, 30 mM of each inhibitor sugar was added to
the assays with L-glucose as a control. For the kinetic assays, increasing concentrations
from 0 to 25 mM of 2-DG containing 3 μCi 3H-2-DG were used. For all experiments, ten
or more oocytes were used in each assay and the oocytes were incubated in uptake
solutions for 15 min. Each experiment was carried out individually for at least three times.

2.5.6 Localization analysis of FGT-1 and R09B5.11 in oocytes
cRNA of fgt-1::eGFP or R09B5.11:eGFP fusion construct in vitro transcribed from
the plasmid pSP-fgt1g or pSP-R09g were injected into Xenopus oocytes. The plasma
membrane localization of gfp fusion proteins were observed three days after the injection
under a confocal laser microscopy (Zeiss LSM 510 META Laser Scanning Microscope).
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2.5.7 RNAi in C. elegans
A 112 bp DNA fragment of fgt-1 exon 6 was amplified from the pCR-fgt1 plasmid
with the primer set of fgt1-ds5 and fgt1ds-3 (Table 2.1). The amplicon was inserted into
pCR-blunt II-TOPO vector to form pCR-fgt1ds. To make the dsRNA for RNAi, the DNA
fragment was amplified from the pCRfgt-1ds plasmid with the M13 forward and reverse
primers (Table 2.1) and the PCR product was then used as a template for transcribing the
single stranded RNA (ssRNA) using Sp6 RNA polymerase (Fermentas) and T7 RNA
polymerase (Promega), respectively. The double stranded RNA (dsRNA) was formed
with the complementary ssRNAs and treated with Turbo DNase (Ambion).
RNAi experiments were carried out by injecting the fgt-1 dsRNA into N2 C. elegans
as described previously [29]. The synthesized fgt-1 dsRNA was injected into young adult
worms. Progeny from embryos laid during 12 through 24 hours after the injection were
isolated and observed for various phenotypes described below.

2.5.8 Western blotting and immunostaining
RNAi efficiency was assessed by semi quantitative measurement of FGT-1::eGFP
protein levels in fgt-1::egfp worms with fgt-1 RNAi. Protein levels were analyzed using
Western blotting procedures as described previously [17]. Ten worms were collected in
sample buffer [62.5 mM Tris (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, and 5% (v/v)
2-β-mercaptoethanol]. Samples were incubated in boiling water for 5 min, centrifuged,
and the supernatant was applied for SDS-PAGE. The proteins were transferred to a
nitrocellulose membrane and incubated with an anti-GFP (B-2, 1:250, Santa Cruz
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biotechnologies) or an anti-actin (C4, 1:500, MP Biomedicals) primary antibody for 2
hours at room temperature, and then with a horse-radish peroxidase-conjugated antimouse IgG secondary antibody (1:5000, Amersham) for 1 hour at room temperature. The
membrane was finally washed and detected using the West-Pico chemiluminescent kit
(Pierce).
For the whole-mount immunostaining, mixed staged worms were settled on PolyPrep slides (Sigma), fixed and permeabilized using freeze-cracking followed by methanol
treatment [30]. An anti-IFB-2 primary antibody (MH33, 1:20, DSHB) was applied
overnight at 4 ºC. The Alexa Fluor 555 conjugated anti-mouse IgG secondary antibody
(1:250, Invitrogen) was then applied for 2 hours at room temperature. Immunostained
animals were observed under a confocal laser microscopy (Zeiss LSM 510 META Laser
Scanning Microscope).

2.5.9 Sudan black B staining
Saturated solution of fat staining dye Sudan black B in 60% isopropanol was diluted
to 50% saturated in 60% isopropanol. Wild-type or RNAi-treated C. elegans were
collected and fixed for one hour in PBS and an equal volume of 2x MRWB buffer [160
mM KCl, 40 mM NaCl, 20 mM EDTA, 10 mM spermidine, 30 mM HEPES, pH 7.4,
50% Methanol] containing 1% paraformaldehyde. After the fixation, samples were
washed with PBS and Sudan black B staining solution was added and incubated for 16
hours at room temperature. Worms were then washed by PBS containing 0.05% Tween20 and observed with an optical microscope. Images taken by the microscopy were
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analyzed with Image J software 1.44p (http://rsbweb.nih.gov/ij/) to quantify the levels of
Sudan black B staining. The experiment was repeated at least three times.

2.5.10 Brood size and dauer formation rate measurement
For brood size assay, ten F1 progenies of dsRNA- or buffer- injected worms were
individually put on NGM agar plate and transferred to new plates daily. The number of
hatched progeny was counted daily. Counting was stopped when the worm produced less
than ten progenies per 24 hours.
Dauer formation assay was performed as described previously [31]. Five dsRNA- or
buffer-injected worms were put on individual NGM agar plates for 24 hours in 20 ºC for
laying eggs. After removing the parent worms, F1 progenies were incubated for 60–72
hours in 20 ºC or 25 ºC. Dauer worms were scored visually, and scoring was confirmed
using SDS. Worms were considered dauers if they survived a several minute incubation
in 1% SDS.
Each experiment was repeated individually at least three times.

2.5.11 Statistical analysis
For the uptake and kinetic analyses, any uptake in fgt-1 cRNA-injected oocytes
lower than three times the mean value of water-injected oocytes was considered to be
injection failure and disregarded from the assay. 2-DG uptake in fgt-1 cRNA-injected
oocytes was corrected by subtraction of the mean 2-DG uptake of water-injected oocytes
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at the corresponding concentration and incubation time. Statistical significance was
determined by the student’s t-test, Tukey-Krammer honestly significant difference (HSD)
test, and Dunnett’s one-way ANOVA, as indicated in individual figure legends, and the
analyses were carried out using JMP 8.0 software (SAS Institute Inc.). Plots and curve
fitting analysis for the Michaelis-Menten equation were carried out using GraphPad
Prism 5.04 (GraphPad Software Inc.).
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2.8 Figures
Loop6
GLUT4
fgt-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3
100 aa

Figure 2.1. Structural schematic representation of GLUT candidate genes in C.
elegans, comparing with human GLUT4.
The amino acid sequence of individual C. elegans genes was obtained from Wormbase
(http://www.wormbase.org/). Blue boxes indicate the predicted transmembrane domains
by Wormbase and the dashed boxes in R09B5.11 indicate the missing predicted
transmembrane domains. Red filled circles indicate potential N-glycosylation sites
predicted

by

NetNGlyc

(http://www.cbs.dtu.dk/services/NetNGlyc/).

Arrowheads

indicate known functionally important residues found in human GLUT4: R92, R153,
R333/4, and E393 [11]. The predicted conserved long loop 6 is indicated by red dashed
circles.
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Figure 2.2. Amino acid sequence alignments of human GLUT1-4 and C. elegans
FGT-1 and R09B5.11.
A. Alignments of the deduced amino acid sequences of FGT-1, R09B5.11 and human
GLUT1-4 were performed with the CLUSTAL W program with open gap penalty = 10
and gap extension penalty = 0.05. Residues that are highlighted by black shading
background represent absolutely conserved amino acids and the gray shading indicates
four or more conserved residues at that positions. Regions of presumed transmembrane
domains (TM) [32] are indicated by the numbered dashed lines, and the functionally
important residues for glucose uptake activity are given by the “F” letters at the top of the
sequence alignments. In addition, the highly conserved amino acids are shown on the
bottom of the sequence alignment. B. Phylogenetic tree of the aligned sequences in (A)
by the CLUSTAL W. Scale bar indicates relative branch lengths obtained from
CLUSTAL W alignment result.
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Figure 2.3. Glucose transport activity and kinetics of C. elegans GLUT candidates in
Xenopus oocytes.
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A. Analysis of 2-deoxy-D-glucose (2-DG) transport activities of FGT-1, R09B5.11,
C35A11.4, F53H8.3, F48E3.2, F13B12.2, Y61A9LA.1, K08F9.1, and Y37A1A.3 in
Xenopus oocytes. Water or the cRNA of C. elegans genes or hGLUT1 was injected into
oocytes and the oocytes were incubated in 10 mM 2-DG containing 2-deoxy-D-[1-3H]glucose (3H-2-DG) for 15 min before counted. Error bars represent SEM (n ≥ 31).
Statistical analysis was conducted using Dunnett’s one-way ANOVA before TukeyKramer HSD test, with water injected sample as the control group (***P < 0.001). B. and
C. Plasma membrane localization of FGT-1 and R09B5.11. eGFP fusion protein of FGT1 (B) or R09B5.11 (C) were individually expressed in oocytes and observed under a
confocal laser microscopy. D. Analysis of 2-DG transport activities of FGT-1::eGFP and
R09B5.11::eGFP fusion proteins in Xenopus oocytes. Water or the cRNA of fgt-1, fgt1::egfp, R09B5.11 or R09B5.11::egfp was injected into oocytes and the oocytes were
incubated in 10 mM 2-DG containing 3H-2-DG for 15 min before counted. Error bars
represent SEM (n ≥ 27). Statistical analysis was conducted using Dunnett’s one-way
ANOVA before Tukey-Kramer HSD test, with water injected sample as the control group
(***P < 0.001). E. Inhibition of glucose transport activity of FGT-1 by phloretin. The
fgt-1 cRNA-injected oocytes were incubated in 10 mM 2-DG with 3H-2-DG and
increasing concentrations of phloretin from 0 mM to 200 uM for 15 min. The 2-DG
uptake of fgt-1 cRNA-injected oocytes was corrected by the uptake of water-injected
oocytes. Error bars represent SEM (n = 10). F. Kinetic analysis of 2-DG uptake by FGT1. The fgt-1 cRNA- or water-injected oocytes were exposed to increasing concentrations
of 2-DG (0-30 mM) containing 3H-2-DG for 15 min. Points represent 2-DG uptake of fgt89

1 cRNA-injected oocytes after correction for the uptake of water-injected oocytes. Error
bars represent SEM (n ≥ 13). Michaelis-Menten nonlinear analysis was conducted in
GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA).
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Figure 2.4. Hexose sugar substrate specificity of fgt-1.
Oocytes injected with either fgt-1 cRNA or water were exposed to 10 mM 2-DG
containing

3

H-2-DG and 30 mM concentrations of L-glucose, D-glucose, 3-O-

methylglucose (3-OMG), D-mannose, D-galactose or D-fructose, for 15 min. 2-DG
uptake from water-injected oocytes was subtracted from fgt-1 cRNA-injected oocytes.
Error bars represent SEM (n = 40). Statistical analysis was conducted using Dunnett’s
one-way ANOVA before Tukey-Kramer HSD test, with L-glucose as the control group
(**P < 0.01, ***P < 0.001).
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Figure 2.5. Cellular and subcellular localizations of FGT-1 in C. elegans.
The fgt-1::egfp fusion construct under the control of fgt-1 promoter was injected into C.
elegans and expression of FGT-1::eGFP fusion protein was visualized with a confocal
laser microscopy. A: whole animal, B: embryos inside of a parental worm, C: higher
magnification image of mid-body. For each panel of A to C, GFP fluorescence was
shown alone or as a merged picture with differential interference contrast (DIC) images.
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D-H. Immunostaining of apical membrane marker IFB-2 for fgt-1::egfp embryos.
Subcellular localizations of FGT-1::eGFP (green) and IFB-2 (red) were observed under a
confocal laser microscopy. D: FGT-1::eGFP, E: IFB-1 immunostaining, F: Merged image
of D and E. G: the higher magnification of the white box area in F. H: Merged image of
eGFP fluorescence and DIC images. I. Schematic diagram of an intestinal cell with
subcellular localizations of eGFP (green) and IFG-2 (red). The potential adherent
junction (AJ) is indicated by dark box.
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Figure 2.6. Cellular localizations of R09B5.11 in C. elegans.
The R09B5.11::egfp fusion construct under the control of R09B5.11 promoter was
injected into C. elegans and expression of R09B5.11::eGFP fusion protein was visualized
with confocal laser microscopy. GFP image and merged picture of GFP with DIC image
in L2 stage (A-D) or three-fold embryo (E and F) are shown. Left- and right-lateral
strings of seam cells (A and B) and individual seam cells (C and D) are visualized.
Arrowheads indicate each seam cell.
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Figure 2.7. Functional analyses of fgt-1 on fat storage, dauer formation and brood
size in C. elegans.
A. The expression of the fgt-1::egfp fusion protein was detected by Western blotting
analysis using an anti-GFP antibody in the wild-type worms (wt) injected with (+) or
without (-) the fgt-1 double stranded RNA (dsRNA, RNAi). B. The intensities of the
fusion protein in A were quantified by Image Lab Software and normalized to β-actin
levels. Error bars represent SEM (n = 4). C, D, and E. Fat accumulation in the fgt-1 RNAi
wt (C) and daf-2(e1370) mutant worms (D) as well as fgt-1(tm3165) mutant animals (E,
no RNAi) was measured by sudan black B staining. Staining intensity was quantitated
using Image J (NIH). Error bars represent SEM (n ≥ 41). Statistical analysis was
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conducted using student’s t-test (**P < 0.01, ***P < 0.001). F and G. Comparison of the
effects of fgt-1 knockdown on dauer formation rate (F) and brook size (G). In F, wildtype and daf-2(e1370) worms were incubated in either 20 ºC or 25 ºC. Error bars
represent SEM (n ≥ 9 and 25 for F and G, respectively). Statistical analysis was
conducted using student’s t-test.

96

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

GLUT1
GLUT2
GLUT3
GLUT4
FGT-1
R09B5.11
C35A11.4
F53H8.3
F48E3.2
F13B12.2
Y61A9LA.1
K08F9.1
Y37A1A.3

:
:
:
:
:
:
:
:
:
:
:
:
:

*
20
*
40
*
60
*
80
---------TM1-------------------------------------------MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYG-------------------------------------MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDD
-------------------------------------MGTQKVTPALIFAITVATIGSFQFGYNTGVINAPEKIIKEFINKTLTDKGN-----------------------MPSGFQQIGSEDGEPPQQRVTGTLVLAVFSAVLGSLQFGYNIGVINAPQKVIEQSYNETWLGRQGP
-------MGVNDHDVSVPLQEVQSRTVEG------------KLTKCLAFSAFVITLASFQFGYHIGCVNAPGGLITEWIIGSHKDLFDMNAVVASQNKNDRSFSNMESESSSNVEKSEKENHHQSLPDENWTPFLFFCISSIALASFQDGFQIGCINAPGPLIIDWIKKCHFELFG-------------------------------------MVEAPSFRMICVAVITSIAGSFHFGFNLVLTNPSQEAFLNFMNQTLAKRFDG
-----------------------------------------MVTSRYLITVTTVVLGGSAQFYSYGVVNPAQVVITDWINQTYIDRYKA
--------------------------------------MQKLNWKLLILSAVLAITAIFQMGYTNAYPNTAIGSFRIFLNESANEPYT----------------MKQVTAAVPNAIFGQNSFMIRNVIEDQGKVVFICLITILLSILPVGYYIVLLNVPEKVFQAFIFDHFENIFG--------MPSHSNGPRGSIASDDSQAPLIEADDAQRRRVMPSLSIHILSIALCLSSGFQQGYIASVLNQPYAQIEQFINSSWIERTGH
-------------------------------------MGETPSFRMLIVAVITSMAGSFHYGYNLVLTNPSQDAFLSFMNQTFAKRFDG
----------------------MSSSGGNVAIIATQRAKKWPPIRTSLMAIIVAFGSSFSFGFQLLITNPAQGAFIKFLNASKHSNNPD
gy
N
*
100
*
120
*
140
*
160
*
1
-----------TM2--------F --------TM3-------------------------------------ESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVL
RKAINNYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGWLGDTLGRIKAMLVANILSLVGALL
---------------------------------APPSEVLLTSLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLIVNLLAVTGGCF
------------------------------EGPSSIPPGTLTTLWALSVAIFSVGGMISSFLIGIISQWLGRKRAMLVNNVLAVLGGSL
---------------------------------KELSRENADLAWSVAVSVFAVGGMIGGLSSGWLADKVGRRGALFYNNLLALAAAAL
---------------------------------EVLSQYQADFIWSVAVSMFSVGGMFGSFCSGFLADKFGRKSTLLYNNILALLAAVC
----------------------------------GLSDNTLQNIWSFVVAILFLGALAGSFSIRLIADWIGRKNGLYISIAVGVLAGGM
P----------------------------------LSLTVSNVIWSFVVSSIAIGAILGASFTRIIGEKYGRRNGMFFNGILNVFAALF
-----------------------------------LSNSEFEWAWSAMLAIYFIGFAAGSVISAGVADRIGRKWTLFLGTCGSLLSSLI
---------------------------------LQLSKTEESLVWSLTVSSQGVGALIGCLIVSPISKFGAKDVLMRLNNVILIAGSLL
P----------------------------------ISDSTLHLLWSLLNVCFPIATIFGQFLAGWMCSQFGRKHTALIASFLYIPGALL
----------------------------------GLSDHTLQNIWSFVVAVLFLGALAGSFSIPFIAEGVGRKNGLYISISVGVLAGGM
----------------------------------DNELSHLENEWSFIVAIFFLGSATGAFLIKTVAERFGRKKGVIVSLFAQVTSSML
Ws v
g
g
gr
80
*
200
*
220
*
240
*
260
----------TM4--------F
F-------TM5------------------TM6--MGFSKLGK-SFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPA
MGFSKLGP-SHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRA
MGLCKVAK-SVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAFGTLNQLGIVVGILVAQIFGLEFILGSEELWPLLLGFTILPA
MGLANAAA-SYEMLILGRFLIGAYSGLTSGLVPMYVGEIAPTHLRGALGTLNQLAIVIGILIAQVLGLESLLGTASLWPLLLGLTVLPA
MGLAKSVG-AYPMVILGRLIIGLNCGFSSALVPMFLTEISPNNLRGMLGSLHQLLVTIAILVSQIFGLPHLLGTGDRWPLIFAFTVVPA
LSTSKLFN-FYPMIVFGRFLVGLNCGITSGLVPMFLTELAPANLRGKCGSFHQLNISVAIVLSQALGLPQIFGTQVGWPYIFACVAIPT
SIASKFIP-LFELYIASRIVMGWSVSVSLGLSALFLSEASPKQNRGAIGMMTGTCVQLGTVCGSVIAMPQIFGTEDLWWLIYATEIGIM
ELVAKRFS-SPELLIFGRFVYGINMGLSSGLVPMYLMEITPYKYRGPAGTLHQIAVAFSDWFSLLIGLPEVLGDQNNWPLAFALPGLPA
ALFAIILK-MPLMFGFSRLVMSLSAAISMNGLILLFQESSPSHMRGLISFNAEMAFVITNLIGGLFGMQSILGQNIVG--LIAVSIIPS
MFLSYWIT-FPIAFIVGRILTGVYTGLACAFAPLYLQQIIPKNIKGSMSCFLHIAVCFGSSLGAIFSLPFMFGSETTWPILVVLPAGFG
CAAAKWCFPAFELLFVGRIIWSLANGVNTVNATVWIVECAPPQIRGRMAAMQEFFMALGSLLTQAVGVP--FSTDELWPYNFLPNCAVV
SIASKFIP-LFELYIISRVVMGWSVSVSLGLSGIFLSEASPKQNRGAIGMMTGTAIQLGTVVGSVVAMPQIFGTDDLWWVIYATEIGIM
TIVSFWIV-NHILFIFARFLMGVGITISMGIAAMFVTESSPAYCRGVSSLINGVLLQLSITVGAVMAMPNVLGNETHWWYLYLFQLIIN
i R
g
e P
rG
g
w
*
280
*
300
*
320
*
340
*
--LLQCIVLPFCPESPRFLLINRNE--------ENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSP-----------ILQSLLLFFCPESPRYLYIKLDE--------EVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTNS-----------ILQSAALPFCPESPRFLLINRKE--------EENAKQILQRLWGTQDVSQDIQEMKDESARMSQEKQVTVLELFRVS-----------LLQLVLLPFCPESPRYLYIIQNL--------EGPARKSLKRLTGWADVSGVLAELKDEKRKLERERPLSLLQLLGSR-----------VLQLALLMLCPESPKYTMAVRGQ--------RNEAESALKKLRDTEDVSTEIEAMQEEATAAGVQE-KPKMGDMFKG-----------FLQLATIPFCVESPKYLISKLND--------REEARRILEKLRGHTKVDEELEHMVQETMVTVEPLHQPGYVSLFKG-----------LFFGAALPFFPESPGFLIQRGA---------TEAATKSIAYYYNCEIDEAEKHLNEIKEEQKNSTKNFKMMDIVRKK-----------LALVCILPFCPESPKYTLGTKHD--------RDKALKDVELLIGKEQAPHMFESIVREVALD--EGDGTFRELFTRP-----------SVACFLTVFLKESPKYLFLKKHD--------ATEAGRALQFYQNIKDEEEKMNVLNDLKLEKEEMGHQKNGSLFDIM-----------IIMLAASYFIPDTPNNLLQMGRY---------TEAIESIKFYYDIEDSDEDEIIKEYWDMVPEMPEQLSLCSAFSNS-----------VVSMVMFSWVAESPQFIMEKYND--------VDRARKALAQYHGVSEDDPSVESEIRICEQSIGKNKEKKKTAGGIESEHSGMEIMFMP
LVFGAALPFFPESPGYLIQKGS---------LESATISISFYYKCEKEEADKHVKEIQKEQMNSTKKFTMLDVIQQK-----------TTVLVILPWVHESPSYLASQDIKHHELHAMFKAKIVASVKFYHGISDPEAEVFADNLIETHQITRSQESIISVWKSP-----------f esP l
a
360
*
380
*
400
*
420
*
440
---------TM7----------------TM8-------- F
FF
------------AYRQPILIAVVLQLSQQLSG-INAVFYYSTSIFEKAGVQ--QPVYATIGSGIVNTAFTVVSLFVVER--AGRRTLHLIGL
---------SYRQPILVALMLHVAQQFSG-INGIFYYSTSIFQTAGIS--KPVYATIGVGAVNMVFTAVSVFLVEK--AGRRSLFLIGM
---------SYRQPIIISIVLQLSQQLSG-INAVFYYSTGIFKDAGVQ--EPIYATIGAGVVNTIFTVVSLFLVER--AGRRTLHMIGL
---------THRQPLIIAVVLQLSQQLSG-INAVFYYSTSIFETAGVG--QPAYATIGAGVVNTVFTLVSVLLVER--AGRRTLHLLGL
---------ALLWPMSIAIMMMLAQQLSG-INVAMFYSTVIFRGAGLTGNEPFYATIGMGAVNVIMTLISVWLVDHPKFGRRSLLLAGL
---------DNQWPMIVSILMMFSQQFSG-ISAVTFYSTLIFKRNGLSGNEPMYATVGFGCIKLIATFGCLFLIDHPKFGRKRLHIAGL
---------SLRDKAFIGVVVTFAMSFSG-VAVINAFAFDILKDTGLKVLEASLANDAISVVSMISSIVAAVIVDR--NGRRPLLLISF
---------DLRIPLAVSIIVMIAQQFTG-CTAVFAFSTDMFLNAGLTPVIARFSTLAIGIVYFLFACTSPFLIHK--VGRRWLSLFQL
---------ANQPVRRGFLLGLATMQLTASVWPVVFYSTDFLMDAGFSYELSESVSTGMLFLSSLSTIVGMFIVEK---YSRKWLLIGT
---------SIRRGILLGMVVSATQIFSG-SMVTISYSTEMFEAVSFIDILVPFLPALGSILSILLTIPALRWVET--RGRRPLLLKTL
WRAKDQTSRLIRYCAWVGVMVKIAYVFTGARSLRGYSTFILYTLSHFTYSQATWLSFATGLLRLPFTLVPVFLVDR--LGRRPLIIVSM
---------SLRDKAFVGAVVTFVMSFSG-VAVISAFAFEILVNTGLNVLQASLANDATTIVSVISSVLAIAIIDK--NGRRPLLLISL
---------FNRRGTLLGMMVTFSMAMSG-ITVINAFAFEILMNVGMKQDTAAIANAAICFFSFAGILVSTKIIDH--FGRRPLLISTF
r
sg
g
grr l
*
460
*
480
*
500
*
520
*
-----TM9----------------TM10-------F
F
F -----TM11-F-------AGMAGCAILMTIALALLEQL--PWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQL
SGMFVCAIFMSVGLVLLNKF--SWMSYVSMIAIFLFVSFFEIGPGPIPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADF
GGMAFCSTLMTVSLLLKDNY--NGMSFVCIGAILVFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAHY
AGMCGCAILMTVALLLLERV--PAMSYVSIVAIFGFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGFSNWTSNFIIGMGFQYVAEA
TGMFVSTLLLVGALTIQNSGGDKWASYSAIGFVLLFVISFATGPGAIPWFFVSEIFDSSARGNANSIAVMVNWAANLLVGLTFLPINNL
SGMCISSILIVITLTLSNAG-YHWASYMNVLFILSFVVTFAFGPGPIPWFFTSELFDSATRGRAAAVSATSNWVANWMVGLTFLPINNI
AGILVCNLIIFALMFTFYKFENHVLGFILICFICIFTFFFALGPGPLCYFINAELVGQAARSAAQSWASVIQMLSRFVIVTAFLPMKNQ
ASCMVALMLLSLFTFLQNYENIEWARYGTIFSLVFYMCVYGVG-SPIPWIIASELFTQQFRATAVTVSVFVAWTFAFIVSTSYLPFQQL
ASVNIAAILVFSLSAILSHY-WTWIGYGCIICLILHGISYSVAMGPIAWFITSELVPINFRAASQSLVLALNHTVALVLAFLTFPLYKT
MFCIIANVFLLIFTLISSDS-SGWASWGFAAAFFMYGIGYNLGVGPVAYFLPAELVPPEAASASLGAAVAVNWICTITTTLFYYPLSKT
LVSFVSILVMIIAININGEL-----KYATFIGLTVLLLVNTCGIGSVSRFYAAELVPRNLLLSSVSTLTMFEALTKIGVEFAFYPTANV
AGILICNLIIFGLMFTFDKFGNQVLGFILIFFICIFQFFFALGPGPLSYFINAELVGQDARSAAQSWASVVQMISQFSIITAFLPMKNQ
GCLAVVNVVIVGLMYTFAETQNQIVSYFLISAICMFNFLFAMGPGPLSMFITGELVPQNCRSASSVWTNAVMAVVRFLILTFYLPVKNM
g gp
f
El
r
540
*
560
*
580
*
600
*
620
--------TM12-------CGPYV--FIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQG-GASQSDKTPEELFHPLGADSQV-------------------- :
CGPYV--FFLFAGVLLAFTLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV--------------------- :
LGAYV--FIIFTGFLITFLAFTFFKVPETRGRTFEDITRAFEGQAHGADRSGKDGVMEMNSIEPAKETTTNV--------------- :
MGPYV--FLLFAVLLLGFFIFTFLRVPETRGRTFDQISAAFHRTPSLLEQEVKPSTELEYLGPDEND-------------------- :
MQQYS--FFIFSGFLAFFIFYTWKFVPETKGKSIEQIQAEFEKRK------------------------------------------ :
IHQYA--FLMFTFFTFTFAIFTWKFVPETKGKSPSAIRKELAFMRKRICS------------------------------------- :
LGEAWSYLILFVAPVAASLVYLYFSLPETKNKNPFEVEEAIEDLPKFPLCGKNRVYDRKQSQEMVLSRQMQLVVDYGSIESLSYRL- :
VGITFS-YFPFIIGLAVFGIFIYVLLPETRDRPMVEIVTEVHHRTASLSAGRPWDASRPPSRQEVQRLLDTMDPRSYSSYDNSTLED :
IGPIT-LVIFFVIPGILCIIMLILYLPETKDKHINVIVEQLRETKAKRKESQKLETEESIGMNKL---------------------- :
VGGWS--YLIFIIPTSIFSMILWRLLPETKFHYKIDPLEIRLLTDLGPSIAPNYGTLDLDEPTLF---------------------- :
IGAQS--LLLFLIPTGVFTVMCYLMCPETSRMTVNEVLNNVAAKKKMDVVFPM---------------------------------- :
LGEAWSYLILFVAPVAVSLVFLYFSLPETKNKSPIEVEEAIEELPKLPLCRSTRSNSIKPI-------------------------- :
TSEFMAYAIFFVVPMIVAVLVIFFLLPETKGRNVEEIREEYERKSLL---------------------------------------- :
g
F
PET

97

:
:
:
:
:
:
:
:
:
:
:
:
:

53
52
51
66
69
88
52
48
50
72
81
52
67

:
:
:
:
:
:
:
:
:
:
:
:
:

109
141
107
125
125
144
107
103
104
128
136
107
122

:
:
:
:
:
:
:
:
:
:
:
:
:

197
229
195
213
213
232
195
191
190
216
223
195
210

:
:
:
:
:
:
:
:
:
:
:
:
:

266
298
264
282
281
301
263
258
259
284
304
263
287

:
:
:
:
:
:
:
:
:
:
:
:
:

341
373
339
357
360
380
340
335
336
361
391
340
364

:
:
:
:
:
:
:
:
:
:
:
:
:

428
460
426
444
449
468
429
423
424
449
475
429
453

492
524
496
509
492
516
515
509
488
512
526
490
500

Figure S2.1. Amino acid sequence alignments of human GLUT1-4 and C. elegans
GLUT candidates.
Alignments of the deduced amino acid sequences of C. elegans genes of FGT-1,
R09B5.11, C35A11.4, F53H8.3, F48E3.2, F13B12.2, Y61A9LA.1, K08F9.1, Y37A1A.3
and human GLUT1-4 were performed with the CLUSTAL W program with open gap
penalty = 10 and gap extension penalty = 0.05. Residues that are highlighted by black
shading background represent absolutely conserved amino acids and the gray shading
indicates eight or more conserved residues at that positions. Regions of presumed
transmembrane domains (TM) are indicated by the numbered dashed lines, and the
functionally important residues for glucose uptake activity are given by the “F” letters at
the top of the sequence alignments. In addition, the highly conserved amino acids are
shown on the bottom of the sequence alignment.
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Figure S2.2. Phylogenetic analysis of human GLUT1-4 and C. elegans GLUT
candidates.
Human class I GLUTs and C. elegans GLUT candidates were aligned with CLUSTAL W
and phylogenetic tree was drawn. Scale bar indicates relative branch lengths obtained
from CLUSTAL W alignment result.
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Table 2.1. List of Primers.

Primer Name
fgt1-5utr
fgt1-3utr
R09-5utr
R09-3utr
fgt1up-5sph
fgt1up-3
fgt1cdna-5
fgt1cdna-3xba
R09up-5sph
R09up-3
R09cdna-3sma
fgt1g-5bcl
ppd-3bcl
R09g-5bgl
ppd-3bgl
fgt1ds-5
fgt1ds-3
M13 forward
M13 reverse
C35-5utr
C35-3utr
F53-5utr
F53-3utr
F48-5utr
F48-3utr
F13-5utr
F13-3utr
Y61-5utr
Y61-3utr
K08-5utr
K08-3utr
Y37-5utr
Y37-3utr

Sequences (5' - 3')
AATGGGTGTCAACGACCATG
AACCTATACGTTTCGCAGTG
CAAAGGCTAGACATTCTATAC
TGATTCTAATCCCGACTATG
CATGCATGCTGCGATTTGGAGCGAATCAG
TTCTGCAAAAAAAATTGATTTTTTAGGAG
ATGGGTGTCAACGACCATGATG
GCTCTAGACTTCCTCTTCTCGAATTCGGCTTG
CATGCATGCTTCCGGACTAGCTAGCATAC
CTATCATTTTTATTTTGACTGGCAAC
GGGTGAACATATCCGTTTTCTCATG
CGCTGATCAAATGGGTGTCAACGACCATG
CGCTGATCACAGGGAGAAAGAGCATGTAG
CGCAGATCTCAAAGGCTAGACATTCTATAC
CGCAGATCTCAGGGAGAAAGAGCATGTAG
GAAAGCGCGCTGAAAAAGCTC
TATCTCCCATTTTTGGCTTCTCCTG
GTAAAACGACGGCCAGT
GGAAACAGCTATGACCATG
TAGGTTCGTCTATCACACC
ACCCGCAAATAATTTGAATAG
CAATACCTGAACCTATTTATTC
AGAAGCATTAACCAACAACAG
AGTTTCAGAACCAGTGACAAC
TTATGCTGGCTGTCATTA
TTTCGACTGGTGCATGTGGTG
AGCGATTCAAAACAAAGTTGG
TTGCCTCAATAGACAGCCA
TGTCATACCCGCTTAAAATCG
TGTACCTCCAGTAACTTTG
TTAAATAGGTTTGATTGAATTC
TTACAGGCAACTGAATGTC
ACAAAAACGGGACGAGCC
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Table S2.1. Scores of BLASTP searches of human GLUTs against Wormbase.

Genes
1 R09B5.11
2 H17B01.1a (fgt-1)
3 H17B01.1b (fgt-1)
4 C35A11.4
5 F53H8.3
6 K08F9.1
7 Y51A2D.5 (hmit-1.2)
8 F14E5.1
9 M01F1.5 (hmit-1.3)
10 F13B12.2
11 Y37A1A.3
12 F48E3.2
13 Y61A9LA.1
14 Y51A2D.18
15 K08H10.6
16 ZK829.9
17 Y39B6A.41
18 F11D5.7
19 Y39E4B.5
20 ZK563.1
21 ZK455.8a
22 Y66D12A.13
23 K09C4.5
24 K09C4.1a
25 ZK455.8b
26 C03B1.13
27 B0361.11
28 F11D5.5
29 F17C11.12a
30 F17C11.12b
31 K09C4.4
32 F45E10.2b
33 Y57G11C.23
34 C06H5.6
35 F45E10.2a
36 B0252.3b
37 B0252.3c
38 C53B4.1
39 F52F12.1a (oct-1)
40 F52F12.1b (oct-1)
41 K05F1.6a
42 K05F1.6b
43 T01B11.7 (oat-1)
44 Y51A2D.4 (hmit-1.1)
45 Y82E9BR.16a
46 ZK637.1
47 ZK892.3

class I
GLUT1
GLUT2
GLUT3
3.00E-84 5.00E-75 6.00E-77
7.00E-82 1.00E-83 4.00E-83
9.00E-82 6.00E-83 6.00E-83
2.00E-36 3.00E-28 7.00E-40
5.00E-35 8.00E-29 1.00E-34
7.00E-34 2.00E-25 5.00E-36
4.00E-30 1.00E-27 3.00E-28
2.00E-29 1.00E-24 5.00E-29
2.00E-29 1.00E-33 7.00E-27
1.00E-27 2.00E-32 2.00E-27
9.00E-27 4.00E-20 2.00E-21
4.00E-25 4.00E-23 2.00E-23
2.00E-24 7.00E-21 6.00E-24
2.00E-21 >1e-2
>1e-2
4.00E-21 3.00E-17 3.00E-20
5.00E-20 4.00E-15 4.00E-19
1.00E-19 3.00E-20 3.00E-15
7.00E-12 7.00E-08 1.00E-07
4.00E-10 2.00E-07 4.00E-10
7.00E-10 3.00E-10 2.00E-11
8.00E-10 3.00E-06 1.00E-05
1.00E-09 >1e-2
>1e-2
2.00E-09 3.00E-09 1.00E-09
5.00E-09 2.00E-10 2.00E-06
1.00E-08 4.00E-05 5.00E-05
2.00E-07 5.00E-08 3.00E-04
6.00E-05 >1e-2
>1e-2
9.00E-05 8.00E-09 3.00E-04
2.00E-04 >1e-2
7.00E-03
2.00E-04 >1e-2
9.00E-03
2.00E-04 7.00E-04 5.00E-03
1.00E-03 >1e-2
>1e-2
1.00E-03 >1e-2
>1e-2
2.00E-03 4.00E-03 >1e-2
2.00E-03 >1e-2
>1e-2
>1e-2
5.00E-03 >1e-2
>1e-2
8.00E-03 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
6.00E-03
>1e-2
>1e-2
6.00E-03
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
5.00E-06 1.00E-03
>1e-2
1.00E-27 3.00E-21
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2

GLUT4
6.00E-67
1.00E-66
4.00E-66
5.00E-31
3.00E-24
3.00E-29
3.00E-17
1.00E-16
1.00E-25
9.00E-20
2.00E-22
4.00E-12
7.00E-18
3.00E-18
6.00E-19
2.00E-13
1.00E-13
5.00E-05
3.00E-04
6.00E-06
>1e-2
>1e-2
>1e-2
3.00E-08
>1e-2
6.00E-08
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2

BLASTP scores against human GLUTs
class II
GLUT5
GLUT7
GLUT9 GLUT11
2.00E-59 2.00E-61 2.00E-57 6.00E-45
1.00E-61 4.00E-61 1.00E-61 4.00E-51
1.00E-61 9.00E-61 2.00E-62 4.00E-51
9.00E-23 1.00E-34 3.00E-35 7.00E-28
2.00E-22 >1e-2
1.00E-32 8.00E-22
2.00E-24 2.00E-32 9.00E-36 1.00E-24
1.00E-18 1.00E-19 3.00E-19 1.00E-16
5.00E-22 6.00E-27 2.00E-29 4.00E-13
5.00E-21 1.00E-20 7.00E-18 4.00E-13
3.00E-26 1.00E-23 2.00E-29 5.00E-14
4.00E-16 6.00E-22 4.00E-33 1.00E-21
3.00E-18 5.00E-25 1.00E-18 7.00E-15
1.00E-20 4.00E-21 3.00E-27 7.00E-17
>1e-2
>1e-2
>1e-2
>1e-2
3.00E-16 1.00E-25 1.00E-23 1.00E-20
5.00E-11 3.00E-20 3.00E-20 3.00E-14
2.00E-14 8.00E-22 5.00E-22 9.00E-05
1.00E-06 2.00E-09 2.00E-09 3.00E-04
9.00E-03 1.00E-05 1.00E-12 3.00E-08
1.00E-06 5.00E-06 9.00E-14 8.00E-07
>1e-2
>1e-2
7.00E-06 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
9.00E-05 2.00E-06 3.00E-06 1.00E-04
9.00E-05 9.00E-08 2.00E-09 6.00E-06
>1e-2
>1e-2
2.00E-05 >1e-2
5.00E-03 3.00E-05 1.00E-07 4.00E-05
>1e-2
>1e-2
9.00E-03 >1e-2
9.00E-03 5.00E-04 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
3.00E-04 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
4.00E-04 >1e-2
>1e-2
>1e-2
4.00E-04 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
3.00E-04 >1e-2
3.00E-17 4.00E-18 3.00E-19 2.00E-16
>1e-2
>1e-2
>1e-2
8.00E-06
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
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GLUT6
2.00E-19
9.00E-34
2.00E-33
4.00E-18
1.00E-08
1.00E-13
7.00E-18
1.00E-11
2.00E-18
3.00E-12
1.00E-09
3.00E-08
>1e-2
8.00E-05
2.00E-08
5.00E-11
>1e-2
>1e-2
4.00E-07
1.00E-05
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
5.00E-03
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
1.00E-11
5.00E-19
>1e-2
>1e-2
>1e-2

class III
GLUT8 GLUT10
2.00E-23 1.00E-09
3.00E-38 1.00E-12
3.00E-38 2.00E-12
6.00E-08 >1e-2
2.00E-08 7.00E-07
3.00E-04 1.00E-03
1.00E-20 9.00E-11
2.00E-09 4.00E-06
3.00E-23 4.00E-13
1.00E-13 7.00E-03
8.00E-09 8.00E-03
6.00E-08 4.00E-06
2.00E-04 >1e-2
1.00E-21 >1e-2
2.00E-08 1.00E-06
1.00E-11 1.00E-03
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
3.00E-04
5.00E-04 >1e-2
7.00E-05 >1e-2
4.00E-03 8.00E-03
>1e-2
>1e-2
7.00E-06 >1e-2
4.00E-04 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
6.00E-05 >1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
7.00E-08 >1e-2
2.00E-07 >1e-2
>1e-2
>1e-2
5.00E-14
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2

GLUT12
4.00E-18
5.00E-21
7.00E-21
4.00E-16
2.00E-05
7.00E-11
4.00E-32
8.00E-08
7.00E-38
3.00E-05
2.00E-06
1.00E-04
>1e-2
>1e-2
6.00E-08
2.00E-04
>1e-2
>1e-2
>1e-2
3.00E-06
2.00E-08
>1e-2
6.00E-04
>1e-2
1.00E-07
>1e-2
3.00E-07
>1e-2
1.00E-08
2.00E-08
2.00E-04
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
>1e-2
1.00E-06
>1e-2
>1e-2
>1e-2
>1e-2
4.00E-04
3.00E-41
>1e-2
4.00E-07
1.00E-03
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3.1 Abstract
Insulin regulation of facilitated glucose transporter (GLUT) plays a key role in the
maintenance of glucose homeostasis in humans. To establish Caenorhabditis elegans (C.
elegans) as a research model to study the mechanism underlying insulin regulation of
GLUT due to the well-conserved insulin/IGF-1-like signaling (IIS) pathway and
relatively easy genetic manipulation, we functionally identified FGT-1 as the only GLUT
homologue in C. elegans and showed that FGT-1 is ubiquitously expressed in neurons,
intestine, and body-wall muscles. The function of FGT-1 in animal growth and aging was
dependent on the IIS background, suggesting IIS regulation. Indeed, FGT-1 mediated
glucose uptake was almost completely defective in daf-2 and age-1 mutants. This defect
was only partially related to the approximately 60% decrease in FGT-1 protein and
should also involve other post-translational mechanisms. Moreover, we found that OGA1, an O-GlcNAcase, is essential for the function of FGT-1, implying the potential
regulation of FGT-1 functions by glycosylation. In summary, our study establishes C.
elegans as a powerful model to study the mechanism of insulin regulation of glucose
transport and provides insights into the mechanism of defective tissue glucose uptake in
patients with diabetes.
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3.2 Introduction
Insulin is a central regulator for sustaining glucose homeostasis in human. When blood
glucose levels increase after meals, insulin is secreted from the islets of Langerhans in the
pancreas to activate glucose uptake and utilization in peripheral tissues, mainly muscle
and adipose tissues (Leto and Saltiel 2012). This stimulation is primarily mediated by the
insulin-induced subcellular translocation of the insulin-sensitive facilitated glucose
transporter 4 (GLUT4) in muscle and fat cells. GLUT4 is stored in intracellular vesicles
under unstimulated conditions, and following the activation of insulin signaling, GLUT4containing vesicles translocate to the plasma membrane to facilitate glucose uptake from
the blood (Saltiel and Kahn 2001; Leto and Saltiel 2012). In patients with type II diabetes,
the regulation of GLUT4 by insulin is defective, and muscle and fat cells become
unresponsive to insulin signals, which is termed insulin resistance (Pessin and Saltiel
2000; Saltiel and Kahn 2001). Although the mechanisms underlying insulin resistance
have been under extensive investigation, the precise mechanisms remain largely
unknown.
Insulin signaling is highly conserved in the animal kingdom, including
Caenorhabditis elegans (C. elegans). In C. elegans, most of major signaling molecules in
the insulin/IGF-1-like signaling (IIS) cascade are well conserved, and IIS has been
known to play important functions in many physiological processes such as reproduction,
growth, metabolism, and aging (Lapierre and Hansen 2012; Gems et al. 1998; Kimura et
al. 1997; Tomioka et al. 2006; Zarse et al. 2012). For instance, knockdown of DAF-2, the
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only homologue of the mammalian insulin/IGF-1 receptor, dramatically increases the
lifespan of C. elegans (Gems et al. 1998; Friedman and Johnson 1988; Kenyon et al.
1993). This lifespan extension is dependent on DAF-16, the homologue of mammalian
FOXO transcription factor; in the daf-2;daf-16 double mutant animal, the longer lifespan
is essentially eliminated (Kenyon et al. 1993). Because of its advantage of relatively easy
genetic manipulation and the availability of a large collection of mutant strains, in
addition to its many other unique advantages for study such as a short lifespan and quick
turnover, C. elegans may be an attractive model system to study the mechanisms
underlying insulin regulation of glucose transport.
To explore C. elegans as a model system for the study of insulin regulation of
glucose transporter functions, we characterized 9 facilitated glucose transporter
candidates in C. elegans (FGT) based on their high sequence homologies to human
GLUTs in our previous study (Kitaoka et al. 2013). FGT-1 was identified as a sole
functional counterpart of GLUT in C. elegans with the ability to transport glucose in
Xenopus oocytes. It also showed broad transport activities for other monosaccharides,
including mannose, galactose, and fructose (Kitaoka et al. 2013). The localization of
FGT-1 was mainly restricted to the digestive tract when expressed under its 2 kb
promoter sequence (Kitaoka et al. 2013), suggesting that there are other unidentified FGT
isoforms in other tissues or that the 2 kb FGT-1 promoter sequence cannot faithfully
represent its endogenous promoter function. In addition, in C. elegans, FGT-1 was found
to be involved in lipid metabolism but not in dauer formation and reproduction (Kitaoka
et al. 2013). Because all of these processes are known to be regulated by IIS (Gems et al.
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1998; Kimura et al. 1997), our previous findings were not able to determine whether
FGT-1 is regulated by IIS in C. elegans.
In the present study, we investigated the tissue localization of another FGT-1
alternative splicing isoform, FGT-1B, and re-examined the tissue localization of FGT-1A
in response to a longer promoter sequence. We showed that FGT-1 is regulated by IIS by
comparing the phenotypic differences in growth, lifespan, and glucose uptake between
FGT-1 mutants in wild-type (wt) or IIS mutant backgrounds. We further investigated the
regulatory mechanisms of IIS on FGT-1 function.

3.3 Results
3.3.1 Tissue localization and glucose transport activity of FGT-1A and -1B
Because FGT-1(A) was identified as the sole functional GLUT homologue in C. elegans
and its expression was mainly observed in the digestive tract in our previous study, we
hypothesized that another FGT-1 splicing isoform, FGT-1B, is expressed in other tissues.
FGT-1B utilizes a distinct exon 1 from FGT-1A and, therefore, has a slightly different
promoter sequence (186 bp of extra sequence at the 3’ end, Fig. 3.1A). To determine
whether FGT-1A and -1B have isoform-specific tissue localizations, we expressed FGT1A::GFP and FGT-1B::GFP under the corresponding 2 kb upstream promoter sequences
of fgt-1a and fgt-1b in wt C. elegans. FGT-1B showed the same localization as FGT-1A:
primarily in the pharynx and intestinal cells (Fig. 3.1B, C). The glucose transport activity
of FGT-1B was also compared with FGT-1A in Xenopus laevis oocytes. The uptake
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activity of FGT-1B for 2-deoxy-D-glucose (2DG, an un-metabolized glucose analogue)
did not differ from that of FGT-1A (Fig. 3.1D), which indicated that the small structural
difference between FGT-1A and FGT-1B at the N-terminus does not alter sugar transport
activity.
To examine whether the 2 kb upstream sequence of FGT-1 faithfully represents
the endogenous localization of FGT-1, we reanalyzed the tissue localization of FGT1A::GFP driven by a longer 5 kb promoter sequence. As shown in Fig. 3.1E-H, the 5 kb
promoter drove FGT-1A::GFP expression not only in the digestive tract like the 2 kb
promoter but also throughout the body, including in the head neurons, vulva, and body
wall muscle. This observation suggests that FGT-1 may be ubiquitously expressed in C.
elegans and that the 2 kb promoter sequence may not be long enough to include all of the
regulatory elements of the fgt-1 promoter.

3.3.2 The developmental growth and lifespan of fgt-1 mutants were dependent on
the IIS background
To study the functions of FGT-1 in C. elegans development and aging and the effects of
IIS on FGT-1 functions, we first compared the developmental growth rates (growth times
from L1 larvae to young adult) between wt and fgt-1(tm3165) mutant animals as well as
between the fgt-1 mutants in either wt or the daf-2(e1370) mutant background. These
worms were grown on media supplemented with or without glucose or 2DG.
Confirmation of the null function of FGT-1 in the fgt-1(tm3165) mutant is shown in Fig.
S3.1. The null functional mutation of the fgt-1 gene in the wt worm did not change the
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growth rates of the animals on either normal or glucose-supplemented medium (Fig.
3.2A). However, the fgt-1 mutation slightly slowed the growth of the daf-2 mutant on
glucose-supplemented medium (P < 0.05) but not on normal medium (Fig. 3.2A).
Supplementation of 2DG dramatically suppressed the development of wt worms but not
of the daf-2 mutant (Fig. 3.2A). Less than 50% of the wt animals could reach the adult
stage when supplemented with 2DG, and thus their developmental growth rates could not
be determined based on their average time to reach the adult stage from L1 larvae.
Instead, we analyzed the percentages of wt and fgt-1 mutant L1 larvae to reach the adult
stage at the 120-hr time point in the 2DG condition (Fig. 3.2B). This experiment revealed
that almost twice of the fgt-1 mutant worms could reach the adult stage compared to wt
worms at 120 hr (P < 0.05), which suggested that the malfunction of FGT-1 reduced the
toxic effect of 2DG on the development of C. elegans. Although supplementation with
2DG slightly slowed the development of the daf-2 mutant strain, the fgt-1 mutation did
not affect the development rate of the daf-2 mutant in the 2DG condition (Fig. 3.2A).
Next, we analyzed the lifespan of the fgt-1(tm3165) mutant and fgt1(tm3165);daf-2(e1370) double mutant cultured on normal and on glucose- or 2DGsupplemented media. In the wt background, the fgt-1 mutation had no effect on the
lifespan of the worm when cultured under both normal and glucose-supplemented (5 and
30 mM) conditions (Fig. 3.2C and Fig. S3.2A). However, consistent with the above
observations for animal development, the fgt-1 mutant had a longer lifespan than the wt
in the 2DG condition (P < 0.001) (Fig. 3.2C). Both glucose and 2DG supplementation
significantly shortened the lifespan of the wt and fgt-1 mutant worms (Fig. S3.2B). In
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contrast, in the daf-2 mutant background, the fgt-1 mutation [fgt-1(tm3165);daf-2(e1370)]
significantly shortened the animal lifespan on normal medium (P < 0.001) but not on
glucose- or 2DG-supplemented medium (Fig. 3.2D). As has been well established in
previous studies (Lee et al. 2009; Kenyon et al. 1993; Schulz et al. 2007), the daf-2
mutant had a much longer lifespan than the wt (Fig. S3.2C). Glucose supplementation
reduced the lifespan of both daf-2 and daf-2;fgt-1 mutants, however, 2DG
supplementation increased the lifespan of the daf-2;fgt-1 mutant but not the daf-2 mutant
(Fig. S3.2D).

3.3.3 The IIS mutant has impaired facilitated glucose transport activity
Because our above analyses showed that the daf-2 background affects the functions of
FGT-1 in animal growth and lifespan, we examined the activities of facilitated glucose
transport and Na+-dependent glucose transport in wt and IIS mutant animals by
measuring the uptake activities of tritium-labeled 2DG (3H-2DG) in wt and mutant strains
of fgt-1(tm3165), daf-2(e1370), daf-2(e1370);fgt-1(tm3165), age-1(hx546), akt-1(mg306),
and daf-2(e1370);daf-16(mgDf50) in the presence or absence of phloretin, a facilitated
glucose transport inhibitor, or phlorizin, a Na+-dependent glucose transport inhibitor (Fig.
3.3). First, glucose uptake activities in fgt-1, daf-2, daf-2;fgt-1, and age-1 mutants were
similar and approximately 40% lower than those in wt (P < 0.001). The akt-1 mutant also
displayed lower glucose uptake than wt (P < 0.05) but higher uptake than the fgt-1, daf-2,
daf-2;fgt-1, and age-1 mutants (P < 0.05). In addition, glucose uptake activity in daf2;daf-16 did not differ from that in wt (Fig. 3.3A). Second, phloretin significantly
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inhibited 2DG uptake in wt, daf-2, akt-1, and daf-2;daf-16 (P < 0.05) but not in the fgt-1
and daf-2;fgt-1 mutants. Phloretin tended to inhibit 2DG uptake in age-1 (P = 0.058) (Fig.
3.3B). Finally, phlorizin inhibited 2DG uptake in all of the tested strains (P < 0.05) (Fig.
3.3C).

3.3.4 Overexpression of FGT-1 rescued the daf-2(e1370);fgt-1(tm3165) phenotypes
Because the daf-2(e1370);fgt-1(tm3165) double mutant had a significantly lower lifespan
than the daf-2(e1370) single mutant when cultured on normal medium (Fig. 3.2D), we
verified whether overexpression of FGT-1 in the daf-2;fgt-1 mutant could rescue this
phenotype. An FGT-1::GFP expression construct under the control of the 5 kb fgt-1a
promoter sequence was introduced into the daf-2(e1370) and daf-2(e1370);fgt-1(tm3165)
mutants to generate FGT-1 overexpression in the daf-2 and daf-2;fgt-1 mutant strains.
Our previous study confirmed that the FGT-1::GFP fusion protein retains the normal
sugar transport function of FGT-1 (Kitaoka et al. 2013). The expression vector without
FGT-1 cDNA was also introduced into the daf-2(e1370) and daf-2(e1370);fgt-1(tm3165)
mutant strains to generate the vehicle control strains. The lifespan of these transgenic
strains was analyzed. As shown in Fig. 3.4A (upper panel), overexpression of FGT-1 in
daf-2;fgt-1 completely rescued the decreased lifespan (P = 0.017) of daf-2;fgt-1, while
the lifespan of the FGT-1::GFP-expressed daf-2;fgt-1 mutant did not differ from that of
the vehicle-introduced daf-2 strain (P = 0.658). However, overexpression of FGT-1 in the
daf-2 single mutant strain had no effect on the lifespan of daf-2 (Fig. 3.4A, bottom panel).
The FGT-1::GFP-mediated glucose transport activity was verified by phloretin-inhibited
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2DG uptake in the FGT-1::GFP-overexpressed fgt-1, daf-2, and daf-2;fgt-1 transgenic
strains but not in the vehicle-introduced transgenic strains (Fig. 3.4B).

3.3.5 IIS regulates FGT-1 expression
To study the mechanisms underlying the impaired facilitated glucose transport activity in
the IIS mutants, the mRNA level of FGT-1 was analyzed in wt and IIS mutant worms by
real-time PCR. Whereas the FGT-1 mRNA level remained unchanged in age-1(hx546)
and akt-1(mg306) compared to wt, it was approximately 50% higher in the daf-2(e1370)
and daf-2(e1370);daf-16(mgDf50) mutants (P < 0.001) (Fig. 3.5A).
Due to the lack of FGT-1 antibody, we analyzed the effect of IIS on FGT-1
protein expression in the transgenic worms expressing the FGT-1::GFP fusion protein
using an antibody against GFP. The IIS in the transgenic worm was manipulated by
feeding RNAi bacteria of daf-2, age-1, akt-1, or both daf-2 and daf-16 (daf-2;daf-16).
Real-time PCR confirmed the effectiveness of each individual bacteria-mediated RNAi
(Fig. 3.5B). Expression of the FGT-1::GFP fusion protein in the transgenic worm was
decreased by more than 50% by daf-2 and age-1 RNAi (P < 0.05) but not by akt-1 and
daf-2;daf-16 RNAi (Fig. 3.5C, D).

3.3.6 IIS does not appear to regulate the subcellular localization of FGT-1
To assess whether the subcellular localization of FGT-1 is regulated by IIS in C. elegans,
the FGT-1::GFP fusion protein was expressed in wt or daf-2(e1370) strains, representing
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IIS active or inactive conditions, respectively. No visible differences in the subcellular
localization of FGT-1::GFP were apparent in either strain, wherein it was located in the
plasma membrane of, at least, the intestinal cells, which possess adipose cell-like
functions in human (Fig. 3.6A). Next, we semiquantitatively examined the FGT-1::GFP
distributions in the cytosolic and plasma membrane fractions of C. elegans and compared
the distributions in wt and daf-2 strains. There were no significant differences in the
FGT-1::GFP distribution in the membrane fraction (more than 90%) in either strain (Fig.
3.6B, C).

3.3.7 The glycosylation gene OGA-1, an O-GlcNAcase of C. elegans, affects glucose
uptake in animals
In human, N- and O-linked glycosylation modifications are known to regulate the
function of GLUT1 (Samih et al. 2003; Ahmed and Berridge 1999). The amino acid
sequence of FGT-1 does not contain any predicted N-glycosylation sites (NetNGlyc 1.0
Server) (Spiro 2002) but have potential O-linked glycosylation sites. In C. elegans, OGT1 and OGA-1 encode the sole O-GlcNAc transferase and O-GlcNAcase, respectively
(Rahman et al. 2010). To study the potential regulation of these glycosylation genes in
glucose uptake in C. elegans, we first assessed 2DG uptake activity in the ogt-1(ok1474)
and oga-1(ok1207) mutant strains. Whereas the ogt-1 mutant showed the same level of
2DG uptake activity as wt, the transport activity was sharply decreased in the oga-1
mutant (P < 0.001) (Fig. 3.7A). In addition, both phloretin and phlorizin inhibited 2DG
uptake in the ogt-1 mutant (P < 0.001) but not in the oga-1 mutant (Fig. 3.7B, C),
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indicating that the oga-1 mutant strain has impairments in both facilitated glucose
transport and Na+-dependent transport activities. The double mutant of oga1(ok1207);fgt-1(tm3165) showed the same level of uptake activity as the oga-1(ok1207)
mutant, which suggested that the impaired 2DG uptake in the oga-1 mutant resulted from
the impaired function of FGT-1. To examine this possibility, the mRNA and protein
levels of FGT-1 were analyzed in oga-1 mutant or knockdown animals. There were no
differences in FGT-1 mRNA levels between wt and oga-1 mutant strains, as measured by
real-time PCR (Fig. 3.7D). However, knockdown of OGA-1 by RNAi (Fig. 3.7E)
reduced the expression of the FGT-1::GFP fusion protein by 37% (P < 0.001) in FGT1::GFP transgenic worms (Fig. 3.7F, G). Taken together, our data demonstrated that
OGA-1 might be involved in the regulation of expression and function of FGT-1 in C.
elegans.

3.4 Discussion
3.4.1 FGT-1 is the sole functional GLUT homologue and the existence of Na+dependent glucose transport in C. elegans
In our previous study (Kitaoka et al. 2013), we investigated the glucose transport activity
of 9 candidates of GLUT homologues in C. elegans based on their sequence homologies
to GLUTs and found that FGT-1 was the only protein with transport activity for 2DG in
Xenopus oocytes. Feng et al. conducted a similar study and reached the same conclusion
(Feng et al. 2013). In the present study, we provided further evidence supporting that
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FGT-1 is the only functional GLUT homologue in C. elegans: 1) In contrast to wt, the
impaired 2DG uptake in the FGT-1 null function mutant fgt-1(tm3165) could not be
further inhibited by phloretin, a GLUT inhibitor (Lefevre 1959; Zhao and Keating 2007;
Ida-Yonemochi et al. 2012), whereas it could be further inhibited by phlorizin, a SGLT
inhibitor (Ehrenkranz et al. 2005) (Fig. 3.3); 2) Under the control of the 5 kb fgt-1
promoter, FGT-1 was ubiquitously expressed in C. elegans (Fig. 3.1) (Kitaoka et al.
2013), suggesting that FGT-1 may be ubiquitously involved in glucose transport in the
tissues and cells of C. elegans. In addition, the current study showed that two FGT-1
splicing isoforms, FGT-1A and -1B, likely have the same or similar tissue distributions
and glucose transport activity in C. elegans (Fig. 3.1). Furthermore, we also demonstrated
the presence of Na+-dependent glucose transport in C. elegans based on the inhibition of
2DG uptake activity by phlorizin (Fig. 3.3). However, BLASTP searches using protein
sequences of human SGLTs against the C. elegans database (Wormbase) did not reveal
any proteins with significant sequence homology to SGLTs. Thus, the transporters
responsible for Na+-dependent glucose transport in C. elegans remain to be identified.

3.4.2 The physiological roles of FGT-1 in C. elegans
Although FGT-1 is the only GLUT-type glucose transporter in C. elegans, the null
function mutation of fgt-1 gene had no effects on the growth and lifespan of animals
cultured on both normal and glucose-supplemented media, as observed for the fgt1(tm3165) strain (Fig. 3.2). In addition, our previous study showed that the dauer
formation rate and brood size phenotypes were also not affected by fgt-1 RNAi (Kitaoka
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et al. 2013). These observations were surprising because it is well known based on
previous studies that even a small amount of glucose supplementation is sufficient to alter
the growth, fertility, and lifespan of C. elegans (Mondoux et al. 2011; Schlotterer et al.
2009; Choi 2011), which was also confirmed in the present study (Fig. 3.2). The
insensitivity of C. elegans growth and lifespan to the function of FGT-1 may be
explained by the following three hypotheses. 1) Under normal condition, gluconeogenesis
may be a major source of glucose in C. elegans. In particular, unlike mammals,
nematodes can convert acetyl-CoA into oxaloacetate via the glyoxylate pathway
(McElwee et al. 2006; Depuydt et al. 2014). Therefore, nematodes have the ability to
produce glucose from fatty acids, in addition to amino acids and glycerol. Thus, C.
elegans cells may not rely on FGT-1 to take up glucose. 2) Under high glucose conditions,
the residual glucose transport activity observed in the fgt-1 mutant strain may still take up
sufficient glucose to shorten the lifespan of the worm. Almost half of the 2DG uptake
activity was retained in the fgt-1 mutant, and it was not inhibited by phloretin (Fig. 3.3).
Less than half of this residual activity could be further inhibited by phlorizin, indicating a
Na+-dependent mechanism (Fig. 3.3). The remaining residual activity may include
intestinal accumulation of the isotope, but other transport mechanisms cannot be ruled
out. For example, the recently discovered SWEET system may also participate in this
process. The C. elegans genome contains seven SWEET homologues (Chen et al. 2010).
3) The effect of glucose in C. elegans may be dominant in some cell types. For example,
if the concentration of glucose in intestinal cells has a dominant effect on the growth and
lifespan of the animal, FGT-1 would play a minimal role in this process because it is
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located in the basolateral membrane of intestinal cells (Kitaoka et al. 2013) and should
not be involved in glucose uptake from the intestinal lumen by these cells. The
malfunction of FGT-1 would increase the intracellular glucose concentration and
reinforce the effects of glucose, which is supported by the increased fat storage observed
in our previous study (Kitaoka et al. 2013). However, the present study showed that the
toxicity of 2DG in the growth and lifespan of C. elegans was affected by the function of
FGT-1 (Fig. 3.2), indicating that C. elegans may be sensitive to the intracellular
concentration of 2DG.

3.4.3 IIS mutants have impaired FGT-l mediated glucose transport
Although FGT-1 is not required for growth and aging in wt worms, it is required for
animal aging in the daf-2 mutant. The daf-2(e1370) mutant had a lifespan that was almost
twice as long as the wt, but the null mutation of the fgt-1 gene in the daf-2 mutant [daf2(e1370);fgt-1(tm3165)] significantly shortened the lifespan of animals cultured on
normal medium (Fig. 3.2D). Importantly, this lifespan change could be rescued by the
overexpression of FGT-1 (Fig. 3.3). The requirement for the function of FGT-1 in the
daf-2 mutant is not known. There are contradictory reports of gluconeogenesis in the daf2 mutant. Whereas the expression of gluconeogenesis enzymes in daf-2 mutants increases
(McElwee et al. 2006; Fuchs et al. 2010; Depuydt et al. 2014), implying an increase in
gluconeogenesis, the enzyme activity of phosphoenolpyruvate carboxykinase (PEPCK), a
key enzyme in gluconeogenesis, is much lower (Depuydt et al. 2014). If gluconeogenesis
is defective in the daf-2 mutant, the cells may require FGT-1 to take up glucose. However,
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there is no difference in the intracellular glucose concentration between daf-2 and wt
worms (Fuchs et al. 2010). Nevertheless, when the daf-2 mutant was cultured on glucosesupplemented medium, its extended lifespan disappeared, and the mutation of fgt-1 [daf2;fgt-1] had no further effect on the shortened lifespan of the daf-2 mutant (Fig. 3.2D).
High glucose conditions may also result in sufficient intracellular glucose, which
enhances the aging process in daf-2 and fgt-1 mutants due to the residual glucose
transport activity (Fig. 3.3). Intriguingly, the daf-2 mutant could completely tolerate the
toxic effects of 2DG on animal growth and aging, and this tolerance was not affected by
the function of FGT-1 (Fig. 3.2). The mechanism underlying this tolerance and the reason
why 2DG provides a protective effect of the fgt-1 mutation in the daf-2 mutant are not
known. Nevertheless, our data clearly showed that the function of FGT-1 is dependent on
the daf-2 background.
Our above observations for the function of FGT-1 in wt and daf-2 mutant are
contradictory to the results reported by Feng et al., who showed that wt worms with
FGT-1 knockdown by RNAi had an extended lifespan and that this extended lifespan was
reduced in the daf-2 mutant background (Feng et al. 2013). These different observations
might be a result of the differences in the lifespan analysis conditions employed in the
two studies. First, Feng et al. used the RNAi method to knock down FGT-1, whereas we
used the fgt-1(tm3165) mutant, a confirmed FGT-1 null function mutant strain. The RNAi
used in the study by Feng et al. was delivered by feeding bacteria of the HT115 strain,
which is known to affect the metabolic rate and lifespan of the worms to a greater extent
than the more popularly used bacterial strain OP50 (Reinke et al. 2010). In addition,
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RNAi may have potential off-target effects. Second, the lifespan analysis conducted in
the study by Feng et al. utilized FUdR, which may have very little effect on the lifespan
of the wt worm but can have a significant effect on the lifespan of some mutant strains
(van Raamsdonk and Hekimi 2011; Davies et al. 2012). The present lifespan assay was
performed under general laboratory culturing conditions for C. elegans without any
additional treatment, which should reflect more natural responses of the worms.
Although there were differences in the effects of FGT-1 knockdown or mutation
on lifespan between the present study and that by Feng et al., both studies showed that
the function of FGT-1 is dependent on the daf-2 background, suggesting the potential
regulation of FGT-1 function by IIS. Indeed, both studies demonstrated a dramatic
decrease in 2DG uptake in the daf-2 mutant. Our study further showed that in daf-2
mutant animals, 2DG uptake activity was decreased to a level similar to that in fgt-1
mutant animals. The activity did not further decrease in the daf-2;fgt-1 double mutant and
could be inhibited only slightly by phloretin. These results indicated that FGT-1 mediated
glucose uptake was almost completely impaired in the daf-2 mutant. In addition, our data
showed that the impaired function of FGT-1 in the daf-2 mutant was dependent on the
DAF-16 transcription factor because the DAF-16 mutation the daf-2 mutant completely
recovered the decreased 2DG uptake (Fig. 3.3B). Furthermore, our study showed that
2DG uptake was also significantly impaired in other IIS mutants, including age-1 and
akt-1. The uptake observed in the age-1 mutant was similar to that in the daf-2 mutant,
whereas the uptake in the akt-1 mutant was between that of the wt and the daf-2 and age1 mutants (Fig. 3.3B). These observations suggest that AGE-1 may mediate the
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stimulation of FGT-1 function by DAF-2, whereas AKT-1 was only partially involved in
this process. In the IIS cascade in C. elegans, there are at least two additional signaling
molecules downstream of AGE-1: AKT-2 and SGK-1 (Hertweck et al. 2004; Evans et al.
2008). These signaling pathways may also cooperatively function with AKT-1 to mediate
DAF-2 regulation of FGT-1 function. Because 2DG uptake could be inhibited by
phlorizin in all of the tested strains to similar degrees (Fig. 3.3C), Na+-dependent glucose
transport may not be regulated by IIS in C. elegans, which is similar to the phenomenon
observed in mammals.
3.4.4 Regulation of FGT-1 expression by IIS
To study the mechanism underlying the serious defect in FGT-1 mediated glucose uptake
in IIS mutants, we first studied the expression of FGT-1 in IIS mutants. The mRNA
expression of FGT-1 was not decreased in IIS mutants but was even increased in daf-2
and daf-2;daf-16 mutants (Fig. 3.5A), excluding the transcriptional inhibition of FGT-1
expression by IIS. However, the protein level of FGT-1 was substantially lower in DAF-2
and AGE-1 knockdown worms compared to control worms (Fig. 3.5C, D). This
decreased protein expression should at least partially contribute to the impaired FGT-1
mediated glucose uptake in the daf-2 and age-1 mutants. At present, it is not known
whether this decreased protein expression of FGT-1 was due to a decrease in mRNA
stability or translational efficiency, or an increase in protein degradation. It is noteworthy
that the FGT-1 protein level did not decrease in the AKT-1 knockdown animals (Fig.
3.5C, D), indicating that the depressed FGT-1 protein expression was not the only
mechanism responsible for the impaired glucose uptake in the IIS mutants.
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3.4.5 Post-translational regulation of FGT-1
Additional evidence that IIS does not regulate the function of FGT-1 solely by reducing
FGT-1 protein expression in C. elegans is provided by our observation that FGT-1
mediated glucose uptake in the daf-2 mutant was almost completely abrogated (Fig.
3.3B), whereas the protein level of FGT-1 was only reduced to 40% (Fig. 3.5D). Other
mechanisms could account to the function of the remaining 40% of FGT-1 protein. One
possible mechanism is the regulation of the FGT-1 subcellular localization by IIS. In
human, regulation of the intracellular localization of GLUT4 plays a central role in
insulin regulation of glucose homeostasis (Saltiel and Kahn 2001; Leto and Saltiel 2012).
However, we did not observe significant differences in the subcellular localization of the
FGT-1::GFP fusion protein or in its distribution in the plasma membrane fraction
between wt and daf-2 mutant animals (Fig. 3.6). These observations do not support the
occurrence of IIS-induced FGT-1 intracellular translocation in C. elegans, which is
consistent with our preliminary Wormbase search showing no conserved homologues in
the C. elegans genome of some of the key molecules involved in GLUT4 translocation
such as AS160 (Bogan et al. 2003; Sano et al. 2007). However, we must note that our
observations had technical limitations. First, the fluorescence intensity of the fusion
protein in the worms might be overly saturated and thus preclude the discrimination of
any visual differences in subcellular localization. Second, because our plasma membrane
fractions were prepared from the whole animal and because subcellular translocation may
only occur in specific tissues such as muscles, as in human, our membrane fractions from
the whole animal might mask any changes in the plasma membrane of specific tissues.
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Third, our plasma membrane fraction may have contained intracellular membrane
vesicles containing intracellular FGT-1.
Another potential mechanism is the regulation of FGT-1 glycosylation by IIS. In
mammals, the function of GLUT1, a GLUT that is systemically expressed throughout the
body and is responsible for basic cellular glucose uptake, is fine-tuned by tissue-specific
glycosylation modifications (Samih et al. 2000, 2003; Ahmed and Berridge 1999; Pyla et
al. 2013). In the present study, we could only examine the effects of the mutation of
genes involved in glycosylation in C. elegans on the function of FGT-1. Because FGT-1
does not have any predicted N-linked glycosylation sites, we investigated the effects of
mutation of the O-linked glycosylation enzymes OGT-1 and OGA-1. Intriguingly, OGA1, a homologue of O-GlcNAcase, was found to be essential for the function of FGT-1 as
well as Na+-dependent glucose uptake (Fig. 3.7). The total defect in FGT-1 mediated
glucose uptake in the oga-1 mutant could not be solely due to the approximately 30%
decrease in FGT-1 protein and is likely related to modification of the FGT-1
glycosylation status. However, surprisingly, the mutation of OGT-1, an O-GlcNAc
transferase, showed no effect on glucose uptake in C. elegans (Fig. 3.7). This finding
may be explained by the observation that O-linked glycosylation of FGT-1 is not
dependent on the function of OGT-1 but on other factors. Nevertheless, further studies
are required to investigate FGT-1 glycosylation and its potential regulation by IIS.
3.4.6 Concluding remarks
In this study, we demonstrated that in C. elegans, FGT-1 mediated facilitated glucose
uptake is severely defective in IIS mutants and that DAF-2, AGE-1, and AKT-1 are
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involved in the control of FGT-1 function by regulating its protein expression and by
other unidentified mechanisms. The results of our study are important in at least three
research fronts. 1) We establish C. elegans as a powerful and unique model to study the
mechanisms of insulin regulation of glucose transport because of its relative ease of
genetic manipulation. 2) We provide insight into the impaired glucose uptake in patients
with diabetes. Our results suggested the possibility of a largely depressed expression of
GLUT proteins in the tissues of patients with diabetes, who have defective insulin
signaling. 3) C. elegans may be used as a drug-screening model to search for compounds
that stimulate glucose uptake in patients with diabetes.

3.5 Materials and Methods
3.5.1 C. elegans strains and culture
C. elegans strains wt (N2), daf-2(e1370), age-1(hx546), akt-1(mg306), daf-16(mgDf50),
daf-2(e1370);daf-16(mgDf50), oga-1(ok1207), and ogt-1(ok1474) were obtained from the
Caenorhabditis Genetics Center (University of Minnesota), and fgt-1(tm3165) was
provided by the National BioResource Project (Tokyo Women’s Medical University
School of Medicine). The double mutant of daf-2(e1370);fgt-1(tm3165) was constructed
by crossing daf-2(e1370) and fgt-1(tm3165), and the daf-2(e1370) and fgt-1(tm3165)
alleles were confirmed by allele-specific PCR using the primer sets ‘e1370chk’ and
‘tm3165chk’, respectively (Zhang 2011). The double mutant of oga-1(ok1207);fgt1(tm3165) was constructed by crossing oga(ok1207) and fgt-1(tm3165), in which the fgt122

1(tm3165) allele was confirmed by allele-specific PCR with the primer set ‘tm3165chk’,
and the oga-1(ok1207) allele was verified with two sets of primers: ‘ok1207chk’ and
‘ok1207WT’. All of the primer sequences used herein are listed in Table S3.1. The C.
elegans strains were cultivated at 20 °C under standard conditions unless otherwise
specified [24].

3.5.2 Plasmid constructions
All of the PCR reactions used for the plasmid constructions were conducted using highfidelity Platinum Pfx DNA polymerase (Life technologies) unless otherwise specified.
To construct the C. elegans expression vector of FGT-1B::GFP under the control
of the 2 kb fgt-1b 5’ upstream promoter sequence, FGT-1B cDNA was amplified from
the cDNA library of the wt worm with the primer set ‘fgt1bcDNA’, and the amplicon was
inserted into the Sal I site of pPD95.79 (Addgene plasmids #1496). The 2 kb 5’ upstream
region of the fgt-1b gene was amplified from the genomic DNA of wt with the primer
pair ‘fgt1bup2k’, and the amplicon was inserted into the Sph I and Sal I sites of pPD95.79
harboring the FGT-1B cDNA to form pPD-fgt1bg2k. For the expression vector of FGT1A::GFP containing 5 kb of the fgt-1a 5’ upstream promoter sequence, the FGT-1A
cDNA was amplified from the cDNA library of wt with the primer set ‘fgt1acDNA’, and
the amplicon was inserted into the Sma I and Sal I sites of pPD95.79. The 5 kb 5’
upstream sequence of the fgt-1a gene was amplified from the genomic DNA of wt with
the primer pair ‘fgt1bup5k’ and the Qiagen LongRange PCR Kit (Qiagen). The amplicon
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was inserted into the Sph I and Sal I sites of pPD95.79 harboring FGT-1A cDNA to form
pPD-fgt1b5k.
To construct the Xenopus oocyte expression plasmid, the full-length cDNAs of
FGT-1B and mutated FGT-1A and -1B were amplified from the cDNA library of wt or
fgt-1(tm3165) worms, respectively. The primer set ‘fgt1bcDNAX’ was used to clone the
wt and mutated FGT-1B cDNAs, and ‘fgt1acDNAX’ was used for the mutated FGT-1A
cDNA. The cDNA amplicons of FGT-1B and mutated FGT-1A and -1B were inserted
into the Bgl I site of pSP64T (obtained from Gwyn Gould, University of Glasgow)
(Gould et al. 1991) to form pSP-fgt1b, pSP-fgt1atm, and pSP-fgt1btm, respectively.

3.5.3 Generation of transgenic worms
Transgenic worms were generated as described previously (Takashima et al. 2012). The
rol-6d pRF4 (obtained from M. Koelle, Yale University) was used as a co-injection
marker (Kramer et al. 1990; Mello and Fire 1995). To generate the transgenic worm
harboring the FGT-1B::GFP expression vector under the 2 kb FGT-1B promoter, the
pPD-fgt1bg2k plasmid was microinjected into the wt worm. A transgenic line expressing
FGT-1A::GFP under the 2 kb FGT-1A promoter was constructed in our previous study
(Kitaoka et al. 2013). To observe FGT-1A::GFP localization under the 5 kb FGT-1A
promoter, the pPD-fgt1g5k plasmid was microinjected into wt or daf-2(e1370) animals.
For the rescue experiments, pPD-fgt1g5k was microinjected into wt, fgt-1(tm3165), daf2(e1370), and daf-2(e1370);fgt-1(tm3165) strains without pRF4. All of the microinjected
DNA solutions were prepared at a final concentration of 100 μg/mL. Transgenic animals
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bearing the pRF4 marker construct were selected based on the roller phenotype, and other
strains were isolated by GFP reporter fluorescence observed under a confocal laser
microscope (Zeiss LSM 510 META Laser Scanning Microscope).

3.5.4 Glucose transport assay in Xenopus oocytes
The cRNAs of fgt-1a were generated in our previous study (Kitaoka et al. 2013). cRNAs
of fgt-1b, fgt-1a(tm3165), and fgt-1b(tm3165) were synthesized by in vitro transcription
from pSP-fgt1b, pSP-fgt1atm, and pSP-fgt1btm, respectively, using the mMessage
mMachine kit (Ambion). The synthesized cRNA (2 μg/μL) or sterile water was injected
into isolated mature oocytes from Xenopus laevis (stage V and VI) following previously
established procedures (Bentley et al. 2012). The use of Xenopus laevis in the present
study was conducted in strict accordance with the recommendations of the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol
was approved by the Institutional Animal Care and Use Committee of the University of
Vermont (#13-025).
The 2DG uptake analysis of wt or mutated FGT-1A and FGT-1B was performed
in Xenopus oocytes as described previously (Kitaoka et al. 2013; Bentley et al. 2012).
Briefly, cRNA- or water-injected oocytes were incubated in Barth’s medium with 10
μg/mL penicillin and 10 IU/mL streptomycin (Gibco) for three days and then subjected to
the uptake assay using 10 mM 2DG containing 1 μCi 3H-2DG. Ten or more oocytes were
used in each assay, and the oocytes were incubated in uptake solutions for 15 min. Each
experiment was performed independently three times.
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3.5.5 Developmental growth and lifespan assay
The times (hr) required to grow from L1 larvae to young adults were recorded in C.
elegans cultured on normal medium or medium supplemented with 5 mM glucose or 5
mM 2DG. The percentages of L1 larvae of wt and fgt-1(tm3165) on 2DG-supplemented
medium that developed into young adult worms were counted at the 120-hr time point.
For each condition, at least 100 worms were used.
The lifespan was observed in worms cultured on normal medium or medium
supplemented with 30 mM glucose or 5 mM 2DG. Synchronized, normal mediumcultured L4 worms were transferred to each culture condition (day 0), and the surviving
worms were then counted every two days. On each counting day, the worms were
transferred to new plates until completion of their propagation and then transferred to
new plates every four days unless the food bacteria were depleted before that cycle.
Worms that had dried on the plate wall were censored from the analysis. The initial
number of 60 worms was observed in each assay, and each assay was repeated twice. The
survival fractions are expressed by Kaplan-Meier survival curves.

3.5.6 Glucose uptake assay of intact worms
Synchronized young adult worms were washed out from the culture plates and incubated
in M9 saline [22 mM KH2PO4, 22 mM Na2HPO4, 85 mM NaCl, and 1 mM MgSO4] for 1
hr to rinse off the food bacteria. A volume of worms of 10% was collected for protein
126

quantification for normalization of the uptake activity. The remaining worms were
subjected to the uptake assay using 5 mM 2DG containing 3 μCi 3H-2DG in M9 saline in
the presence or absence of 100 μM phloretin or phlorizin. The worms were incubated in
the uptake solutions for 2 hr at 20 °C and then washed thoroughly three times with icecold PBS containing 0.5% Tween-20 prior to lysis in 0.5% SDS containing 60 μg/mL
proteinase K for 1 hr at 55 °C. The radioactivity of the lysed worms was counted using a
Tri-Carb Liquid Scintillation Counter 2900TR (Perkin Elmer Inc.). Each experiment was
performed independently four times.

3.5.7 Feeding RNAi
RNAi feeder plasmids of DAF-2 and DAF-16 were obtained from Addgene (Addgene
plasmid #34833 and #34834, respectively) (Dillin et al. 2002). An RNAi feeder plasmid
of AGE-1 was obtained from Source Bioscience. RNAi feeder plasmids of AKT-1 and
OGA-1 were obtained from GE Healthcare Dharmacon Inc. These plasmids were
transformed into HT115 (DE3) bacteria, and RNAi was performed by culturing the
worms on plates together with these feeding bacteria.

3.5.8 mRNA quantification
The mRNA levels of FGT-1, DAF-2, AGE-1, AKT-1, DAF-16, and OGA-1 were
measured by reverse-transcription quantitative PCR (RT-qPCR) with primer pairs to
amplify FGT1q, DAF2q, AGE1q, AKT1q, DAF16q, and OGA1q, respectively (Table
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S3.1) (Jin et al. 2011). The mRNA levels of CDC-42 and PMP-3, which were analyzed
with primer sets for CDC42q and PMP3q, respectively (Table S3.1), served as internal
controls to normalize the expression of the other mRNAs (Hoogewijs et al. 2008). To
perform the RT-qPCR, the cDNA library was synthesized from the total RNA of
individual strains with poly-T primer and SuperScript III Reverse Transcriptase (Life
technologies), and the cDNA samples were amplified with SsoFast EvaGreen Supermix
(Bio-Rad Laboratories, Inc.) using the CFX96 real-time PCR detection system (Bio-Rad
Laboratories, Inc.). The output data were then analyzed with CFX manager software
version 3.0 (Bio-Rad Laboratories, Inc.).

3.5.9 Plasma membrane fractionation
Membrane fractionation of the worms was conducted as described previously (Gally et al.
2004). Synchronized young adult worms were dissolved in homogenization buffer
[20 mM HEPES pH 7.4, 10 mM KCl, 1 mM EDTA, protease inhibitor cocktail (P8340,
Sigma)] and underwent freezing and thawing in liquid nitrogen three times. Lysed worms
were homogenized with the sonic dismembrator 100 (Fisher Scientific). Sucrose was
added (final concentration of 0.25 M), and the solution was centrifuged twice at 5,000 g
to remove worm debris. A portion of the supernatant was collected as worm lysate, and
the rest was centrifuged at 150,000 g for 1 hr. The resulting supernatant was collected as
the cytosolic fraction, and the pellet was dissolved by homogenization in homogenization
buffer with 0.5% NP-40 and 0.5% Tween-20 and used as the plasma membrane fraction.
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3.5.10 Western blot analysis
Western blotting procedures were conducted as described previously (Kitaoka et al.
2013). Briefly, synchronized young adult worms were homogenized and prepared with
NuPAGE LDS sample buffer (Life technologies) containing 100 mM dithiothreitol. The
samples were incubated in boiling water for 5 min and centrifuged. The supernatants
were subjected to SDS-PAGE, and the proteins were transferred to PVDF membranes.
The membranes were incubated with anti-GFP (B-2, Santa Cruz biotechnologies; 1:500),
anti-RME1 (DSHB; 1:40), or anti-actin (C4, MP Biomedicals; 1:5000) primary antibody
for 2 hr to overnight at room temperature and then with a horseradish peroxidaseconjugated anti-mouse IgG secondary antibody (Amersham; 1:5000) for 2 hr at room
temperature. The membranes were finally washed and detected using the West-Pico
chemiluminescent kit (Pierce). The resulting bands were quantified using Image Lab
software version 3.0 (Bio-Rad Laboratories, Inc.).

3.5.11 Statistical analysis
For the 2DG transport assay in oocytes, any uptake in fgt-1a or fgt-1b cRNA-injected
oocytes less than three times the mean value of water-injected oocytes was considered as
injection failure and discarded from the analysis. The 2DG uptake in fgt-1a or fgt-1b
cRNA-injected oocytes was corrected by subtraction of the mean 2DG uptake of waterinjected oocytes. To quantify the subcellular distribution of FGT-1::GFP, the level of
FGT-1::GFP in whole lysate was normalized to the actin level, and then the ratios of the
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cytosolic and membrane fractions of FGT-1::GFP to the normalized FGT-1::GFP level in
the lysate were calculated.
The statistical analysis of the individual experiments is indicated in the figure
legends, and the analyses were conducted using GraphPad Prism 6.03 (GraphPad
Software) and JMP Pro 11.2 (SAS Institute Inc.).
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3.8 Figure legends
Figure 3.1. Tissue localization and glucose transport activity of the FGT-1 isoforms
A and B
A. Gene structures of fgt-1a and fgt-1b (adapted from Wormbase). The filled boxes
represent exons, and the lines connecting the boxes represent introns. B, C. Tissue
localization of FGT-1B::GFP (B) and FGT-1A::GFP (C) in L2 worms, driven by the
corresponding 2 kb upstream promoter sequences of fgt-1a and fgt-1b. D. 2-deoxy-Dglucose (2DG) uptake activity of FGT-1A and -1B in Xenopus oocytes injected with the
corresponding FGT-1A or -1B cRNA or water. Error bars represent SD (N = 3). The
statistical analysis was conducted using one-way ANOVA with Tukey’s HSD test, and
significant differences are indicated by the different alphabetical letters on each bar (P <
0.001). E-H. Tissue localization of the FGT-1A::GFP fusion protein in L2 worms, driven
by the 5 kb upstream promoter sequence of fgt-1a. GFP images of the whole body at the
L2 stage (E), head (F) and mid-gut (G) of the young adult, and embryo (H).

Figure 3.2. Developmental growth rate and lifespan of the fgt-1-null mutant
A. Growth times (hr) from L1 larvae to young adult were measured in wild-type and
mutant worms of fgt-1(tm3165), daf-2(e1370), and daf-2(e1370);fgt-1(tm3165) cultured
on normal medium or medium supplemented with 5 mM glucose or 5 mM 2-deoxy-Dglucose (2DG). Error bars represent the SD (N = 3). The statistical analysis was
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conducted using one-way ANOVA with Tukey’s HSD test, and significant differences
are indicated by the different alphabetical letters on each bar (P < 0.05). B. The
percentages of L1 larvae that developed into young adult worms at the 120-hr time point
were measured in wild-type and fgt-1(tm3165) in conditions containing 5 mM 2DG.
Error bars represent SD (N = 3). The statistical analysis was conducted using the
student’s t-test (*P < 0.05). C, D. The lifespan of wild-type (N2) and fgt-1(tm3165) (C)
as well as daf-2(e1370) and daf-2(e1370);fgt-1(tme165) worm strains (D) cultured on
normal medium or medium supplemented with either 30 mM glucose or 5 mM 2-deoxyD-glucose (2DG). The survival fractions for each condition are presented as KaplanMeier survival curves. The statistical analysis was conducted using the log-rank (MantelCox) test.

Figure 3.3. Glucose uptake activity in fgt-1(tm3165) and insulin/IGF-like signaling in
mutant worms
A. Intact worms of wild-type and mutants of fgt-1(tm3165), daf-2(e1370), fgt1(tm3165);daf-2(e1370), age-1(hx546), akt-1(mg306), and daf-2(e1370);daf-16(mgDf50)
were incubated with tritium-labeled 2-deoxy-D-glucose (3H-2DG) for 2 hr and evaluated
for 2DG uptake. Uptake in the wild-type worm was set at 1. Error bars represent the SD
(N = 4). The statistical analysis was conducted using one-way ANOVA with Tukey’s
HSD test, and significant differences are indicated by the different alphabetical letters on
each bar (P < 0.05). B-D. Intact worms of wild-type and mutants were incubated with 3H2DG in the presence or absence of phloretin (B), phlorizin (C), or both inhibitors (D) for
137

2 hr and evaluated for 2DG uptake. Uptake in wild-type worms in the absence of any
inhibitors was set at 1. Error bars represent SD (N = 4). The statistical analysis was
conducted using a paired student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001).

Figure 3.4. Lifespan and 2-deoxy-D-glucose (2DG) uptake rescue in the daf-2;fgt-1
mutant by overexpression of FGT-1
A. Lifespan assay of daf-2(e1370) and daf-2(e1370);fgt-1(tm3165) transgenic worms
introduced with the FGT-1::GFP expression vector (oe) or control vector (vehicle)
cultured on medium without sugar supplementation. The survival fractions of each strain
are presented as Kaplan-Meier survival curves. The statistical analysis was conducted
using the log-rank (Mantel-Cox) test. B. The 2-deoxy-D-glucose (2DG) uptake assay in
the presence or absence (control) of phloretin in wild-type (N2) or fgt-1(tm3165), daf2(e1370), and daf-2(e1370);fgt-1(tm3165) transgenic worms introduced with the FGT1::GFP expression vector (oe) or the control vector (vehicle). Error bars represent the SD
(N = 4). The statistical analysis was conducted using the paired student’s t-test (**P <
0.01, ***P < 0.001).

Figure 3.5. Effects of insulin/IGF-like signaling on FGT-1 mRNA and protein
expression
A. The mRNA levels of FGT-1 in wild-type and daf-2(e1370), age-1(hx546), akt1(mg306), and daf-2;daf-16(mgDf50) mutants were measured by real-time reverse
transcription PCR and normalized to the mRNA levels of CDC-42 and PMP-3. The
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mRNA level of FGT-1 in wild-type worms was set at 1. Error bars represent the SD (N =
3). The statistical analysis was conducted using one-way ANOVA with Tukey’s HSD test,
and significant differences are indicated by the different alphabetical letters on each bar
(P < 0.001). B. Transgenic C. elegans expressing the FGT-1::GFP fusion protein were
fed individual RNAi bacteria of daf-2, age-1, akt-1, or both daf-2 and daf-16 and
analyzed for the relative mRNA levels of DAF-2, AGE-1, AKT-1, or DAF-16 by realtime PCR. Error bars represent the SD (N = 3). The statistical analysis was conducted
using the paired student’s t-test (*P < 0.05, ***P < 0.001). C, D. Expression of the FGT1::GFP fusion protein in FGT-1::GFP transgenic worms that were fed control RNAi
bacteria (vehicle) or individual RNAi bacteria of daf-2, age-1, akt-1, and both daf-2 and
daf-16 were analyzed by Western blot analysis with an antibody against GFP (C). Actin
served as an internal control. The relative FGT-1::GFP levels were quantitated (D). Error
bars represent SD (N = 3). The statistical analysis was conducted by one-way ANOVA
with Tukey’s HSD test, and significant differences are indicated by the different
alphabetical letters on each bar (P < 0.001).

Figure 3.6. Subcellular localization of FGT-1 in wild-type and daf-2 mutant worms
A. Localization of FGT-1::GFP under the 5 kb fgt-1a promoter during the L2 stage in
wild-type and daf-2(e1370) worms. B. Western blot analysis of FGT-1::GFP in cytosolic
(Cyt) and plasma membrane (Mem) fractions and whole lysate (Lys) prepared from wildtype and daf-2(e1370) worms with GFP antibody. RME1 is a plasma membrane marker,
and actin was used as an internal control. C. The percentages of FGT-1::GFP in the
139

cytosolic and plasma membrane fractions detected in B. Error bars represent the SD (N =
3).

Figure 3.7. Effect of the mutation of glycosylation genes on glucose uptake and
FGT-1 expression
A-C. The 2-deoxy-D-glucose (2DG) uptake activity in wild-type, ogt-1(ok1474), oga1(ok1207), and oga-1(ok1207);fgt-1(tm3165) was analyzed in the presence of no
inhibitor (A), phloretin (B), or phlorizin (C). Worms were incubated with tritium-labeled
2-DG (3H-2DG) for 2 hr and assessed for the uptake of 2DG. Uptake in wild-type worms
was set at 1. Error bars represent the SD (N = 4). D. mRNA levels of FGT-1 in wild-type
and oga-1(ok1207) were analyzed by real-time PCR and normalized to the mRNA levels
of CDC-42 and PMP-3. The mRNA level of FGT-1 in wild-type worms was set at 1.
Error bars represent the SD (N = 3). E. Transgenic C. elegans expressing the FGT-1::GFP
fusion protein were fed RNAi bacteria of oga-1 or the vector control (vehicle) and
analyzed for the mRNA level of OGA-1 by real-time PCR. Error bars represent the SD
(N = 3). F, G. The expression of the FGT-1::GFP fusion protein in FGT-1::GFP
transgenic worms fed either control RNAi bacteria (vehicle) or RNAi bacteria of oga-1
were analyzed by Western blot analysis using an antibody against GFP (F). ACT-1
served as an internal control for normalization. The relative FGT-1::GFP levels were
quantitated (G). Error bars represent the SD (N = 3). In A, the statistical analysis was
conducted using one-way ANOVA with Tukey’s HSD test, and significant differences
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are indicated by the different alphabetical letters on each bar (P < 0.001). In B-E and G,
the statistical analysis was performed using the paired student’s t-test (**P < 0.01, ***P
< 0.001).
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Figure S3.1. Functional analysis of the mutated fgt-1 gene in the fgt-1(tm3165) strain
FGT-1A and -1B cDNAs were cloned from the fgt-1(tm3165) mutant and transcribed into
their corresponding cRNAs. The cRNAs were individually injected into Xenopus oocytes,
and the oocytes were measured for the uptake activity of 2-deoxy-D-glucose (2DG) in
comparisons with those injected with the cRNAs of wild-type FGT-1A or -1B. Water was
used as a negative control. Error bars represent the SD. The statistical analysis was
conducted using one-way ANOVA with Tukey’s HSD test, and significant differences
are indicated with the different alphabetical letters on each bar (P < 0.001).
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Figure S3.2. Lifespan comparisons between wild-type (N2), fgt-1(tm3165), daf2(e1370), and daf-2(e1370);fgt-1(tm3165) worms cultured on normal medium
(control) or medium supplemented with 30 mM glucose of 5 mM 2-deoxy-D-glucose
(2DG)
A. Lifespan comparison between wild-type and fgt-1(tm3165) worms on glucose medium.
B. Lifespan comparisons of wild-type and fgt-1(tm3165) worms on normal glucose or
2DG media. C. Lifespan comparison between wild-type and daf-2(e1370) on normal
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medium. D. Lifespan comparisons of daf-2(e1370) and daf-2(e1370);fgt-1(tm3165)
worms on normal, glucose-, or 2DG-supplemented medium. The lifespan is presented as
a Kaplan-Meier survival curve. The statistical analysis was conducted using a log-rank
(Mantel-Cox) test.
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Table S3.1. List of primer sets
Name
e1370chk
tm3165chk
ok1207chk
ok1207WT
FGT1q
DAF2q
AGE1q
AKT1q
DAF16q
OGA1q
CDC42q
PMP3q
fgt1bcDNA
fgt1b2kbup
fgt1acDNA
fgt1b5kbup
fgt1bcDNAX
fgt1acDNAX

Forward primer
CGGGATGAGACTGTCAAGATTGGAGATTTCGG
GCGGGGGTTCAGCTGTGTAA
GCAAACAGAAAGGTGAGCTAG
ACGAGCGGTTCCGACGTTAG
TCCAGGAGGGCTTATCAC
GTGGCGTGAGAATGAAGTGAG
CGGAAAGACCAAACTTGGGATC
CAAAGCCTAAGGAAGGACAACC
TCGTCGTCTCGTGTTTCTCCA
ACATTTCCCGATTAAGTATTGACTGTG
CTGCTGGACAGGAAGATTACG
GTTCCCGTGTTCATCACTCAT
AAGTCGACGAAGAAAATTCATTTAAAATAATGTCGGA
CATGCATGCATTTGGAGCGAATCAGGC
AAGTCGACAGAAATGGGTGTCAACGACCATG
CATGCATGCAGACGGCTGAAAGTGCGCTCCAG
TACTGATCAGAAGAAAATTCATTTAAAATAATGTCGGA
TACTGATCAAATGGGTGTCAACGACCATG

Reverse primer
CAACACCTCATCATTACTCAAACCAATCCATG
TATGATACGGAGTTTCGCCA
AACTCAGAAGGCACAGGCTC
TTCCGACGCATTACACTTCC
AATACGGATACTGCGACGGAC
GGAATTTCGTAGAATCCGTTG
CGTAGGCTTCGACGCATAACG
CATGAATCCAACGCTGACGAAC
TTCCATAGGCACCCGGTAGTG
AGATGCTTGCGCTGTTCTGG
CTCGGACATTCTCGAATGAAG
ACACCGTCGAGAAGCTGTAGA
CTTCCTCTTCTCGAATTCG
AAGTCGACGAAATAAATATATATTTTCTAGATTTAGACG
CTTCCTCTTCTCGAATTCG
AAGTCGACGAAATAAATATATATTTTCTAGATTTAGACG
TACTGATCAAACCTATACGTTTCGCAGTG
TACTGATCAAACCTATACGTTTCGCAGTG
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Chapter 4: General Discussion
4.1 Energy metabolism and sugar transport in C. elegans
In C. elegans, energy metabolism has been widely studied, particularly in aging
research. Because of its short lifespan, C. elegans has been used as a primary model
system for aging studies, and these studies have established a close relationship between
the energy metabolism rate and lifespan (Newgard and Pessin 2014). Calorie restriction
can extend the lifespan of C. elegans, whereas high energy supply, such as glucose
supplementation, can dramatically shorten the lifespan of C. elegans (Lee et al. 2009;
Schlotterer et al. 2009; Schulz et al. 2007). Several independent long-lived strains share
some common metabolic profiles, including elevated gene expression and metabolite
levels in energy metabolism pathways such as glycolysis and gluconeogenesis (Fuchs et
al. 2010; Depuydt et al. 2014; Patti et al. 2014). Several regulatory pathways, such as IIS
and TOR signaling, are known to play essential roles in energy metabolism and aging in
C. elegans (Hansen et al. 2013; Rockenfeller and Madeo 2010). Although glucose is an
important energy source in C. elegans, as in other animals, the glucose transporter system
and its regulation by IIS had not been investigated previously. Knowledge in these areas
would help us to use C. elegans as a powerful model system to study the mechanisms by
which insulin regulates glucose transporters because of the many unique advantages of C.
elegans, including relatively easy genetic manipulation and largely available mutant
strains.

151

Our studies have identified FGT-1 as the only functional GLUT homologue
(Kitaoka et al. 2013), however, the reproduction, development, and aging processes
appear to be independent of FGT-1 function in wt worms. This independence can be
explained by compensatory functions of other glucose transporter families, such as SGLT
and SWEET, and by the unique ability of gluconeogenesis to proceed from substrates
such as fatty acids (by the glyoxylate cycle). However, functioning FGT-1 is required in
IIS mutants because FGT-1 knockout reduced the lifespan of the daf-2 mutant worm.
Consistently, IIS mutants have severely defective FGT-1 function and substantially
decreased FGT-1 protein expression. Although why IIS mutants require functioning
FGT-1 in contrast to the wt worms remains unknown, our work established the regulation
of FGT-1 expression and function by IIS in C. elegans.
Incorporating the results of this study into the accumulated knowledge regarding
the energy metabolism of C. elegans, we propose a general model of FGT-1 function and
IIS regulation in sugar metabolism of C. elegans (Fig. 4.1). IIS is normally active in wt
worms, sustaining high FGT-1 expression and possibly stimulating glucose synthesis
rates from glycerol, amino acids, and fatty acids. IIS also inhibits trehalose synthesis
from glucose. In addition, SGLT- and SWEET-types of glucose transporters may be
involved in glucose uptake or efflux, at least in some cell types. Glucose availability is
high in wt worms. Environmental stresses, such as starvation and heat stress, inhibit the
IIS signaling cascades, which activate several stress response mechanisms (Baumeister et
al. 2006). One of these responses is to alter energy metabolism rates including glucose
metabolism pathways. Under weak IIS conditions, FGT-1 expression is low, resulting in
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low glucose uptake. We hypothesize that when IIS is inhibited, the gluconeogenesis rate
is low due to the inhibited enzyme activity of PEPCK (Depuydt et al., 2014), trehalose
synthesis is increased (Honda et al. 2010), and the glycolysis rate is high (Depuydt et al.,
2014). These effects further decrease glucose availability but increase metabolite levels in
the cells, resulting in a longer lifespan by unknown mechanisms (Fuchs et al. 2010;
Depuydt et al. 2014).

4.2 C. elegans as a model for medical research and drug screening
Diabetes is the most prevalent disease with GLUT dysfunction. Our FGT study
in C. elegans provides a powerful model of diabetes study because we observed a severe
glucose uptake defect in IIS mutants. Further study of the mechanisms of this defect may
provide insights into the defective glucose uptake in the peripheral tissues of patients
with diabetes. Although no evidence of an IIS-dependent subcellular translocation
mechanism of FGT-1 function has been observed unlike human GLUT4, IIS mutants
with inhibited FGT-1 expression still remain good models to study the mechanism of
reduced GLUT expression observed in patients with diabetes (Moraes et al. 2014;
Shepherd and Kahn 1999). In addition, even if IIS does not regulate FGT-1 subcellular
translocation in C. elegans, this organism can still be reconstructed to study GLUT4
translocation by taking advantage of its transparent body and by humanizing it with the
expression of GLUT4 and the key genes that are involved in the process of subcellular
translocation and in its regulation by insulin but that are absent in C. elegans. This type of
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humanization of C. elegans has been widely performed and has greatly advanced our
understanding of some human diseases (Sin et al. 2014).
Furthermore, the defective glucose uptake in IIS mutants also provides an
extremely attractive model of drug screening for diabetes treatment. The high-throughput
and cost-effective nature of C. elegans enhances the efficiency of the first chemical
screening step in an intact animal. Chemical compounds that stimulate the glucose uptake
activity of IIS mutant worms, such as the daf-2 mutant, would be strong drug candidates
for patients with both type 1 and type 2 diabetes because the candidate chemical
compounds should increase the insulin-independent glucose uptake. Thus, developing
new technology to measure glucose uptake activity with a small amount of worms and
non-radioactive labeled glucose is important. The fluorescent-labeled 2DG analog
2NBDG (Zou et al. 2005) is an ideal substrate for quantitative, high-throughput screening
using the COPAS system. The recently developed enzymatic 2DG measurement
technique (Zhao et al. 2014) may also be applied in high-throughput drug screening in C.
elegans.
GLUT dysfunction in humans results in several diseases other than diabetes.
GLUT1 deficiency syndrome is characterized by neurological defective symptoms during
development, such as infantile seizures, developmental delay, acquired microcephaly,
and ataxia. Several types of heterozygous mutations of the GLUT1 gene were found to
cause defective glucose transport across the blood-brain barrier (Seidner et al. 1998;
Pascual et al. 2004). Thus, the symptoms of GLUT1 deficiency syndrome may be due to
low glucose concentrations in the cerebrospinal fluid. This syndrome is treated with a
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ketogenic diet, however, no effective drug has been developed thus far (Gras et al. 2014).
Because of the heterozygous dysfunction nature of the GLUT1 gene in this syndrome,
functional GLUT1 remains expressed and capable of transporting glucose in patients.
Therefore, medicines that can stimulate GLUT1 expression levels can enhance glucose
transport activity and alleviate GLUT1 deficiency syndrome symptoms. GLUT2
deficiency syndrome is known as Fanconi-Bickel syndrome, which is caused by
homozygous or compound heterozygous mutations of the GLUT2 gene (Santer et al.
1997; Grünert et al. 2012). The symptoms are hepatomegaly with glycogen accumulation,
fasting hypoglycemia, dwarfism, and renal syndrome with glucosuria and aminoaciduria
(Santer et al. 1998; Grünert et al. 2012). These symptoms are due to a lack of GLUT2
function during glucose diffusion in hepatocytes and glucose reabsorption in the kidney.
GLUT2 knockout mice show similar phenotypes (Mueckler and Thorens 2013). GLUT2
is also expressed in pancreatic β-cells and hypothalamus, and GLUT2 knockout mice
have a diabetic phenotype. However, patients suffering from Fanconi-Bickel syndrome
rarely present diabetes because of GLUT1 and GLUT3 expression in human β-cells (De
Vos et al. 1995). Thus far, no specific drug treatment exists for Fanconi-Bickel
syndrome, where the stabilization of glucose homeostasis and compensation for renal
losses by dietary supplementation are the primary current treatments for this syndrome.
Because functional GLUT2 is not usually found in these patients, medical treatment
could focus on targeting the up-regulation of other glucose transporters such as GLUT9
in hepatocytes and SGLT2 in the kidney. Artery tortuosity syndrome is also associated
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with GLUT10 homozygous mutations (Coucke et al. 2006), although the physiological
relevance of GLUT10 defects in this syndrome is not yet known.
Pharmaceutical companies are unwilling to develop medicines for rare diseases
such as Fanconi-Bickel syndrome and artery tortuosity syndrome because of the low
probability of investment-return (Kontoghiorghe 2014). The establishment of a new costeffective drug development strategy should encourage drug development for these rare
diseases. C. elegans models offer this advantage. In addition, C. elegans has some
molecular mechanisms that are identical to those of humans and that can be humanized
for individual diseases. This organism can be used as a drug screening model for
compounds that increase glucose uptake in specific tissues. One possible target is Olinked glycosylation of GLUTs. Our study has shown that the function of FGT-1 is
strongly affected by the function of the glycosylation gene OGA-1, implying regulation
of FGT-1 by glycosylation in C. elegans. Thus, C. elegans can be an attractive model to
study the glycosylation of GLUTs for new medical approaches.
Finally, our study also showed that FGT-1 knockdown is linked to fat
accumulation in C. elegans. The physiology of elevated fat storage in the absence of
FGT-1 function is intriguing. Extended studies of the underlying mechanisms may reveal
novel ideas of obesity mechanisms and medications for treatment. Thus, C. elegans can
be a model system for obesity studies that target FGT-1 function.
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4.3 Future directions
1) Further investigation of the mechanisms by which IIS regulates FGT-1
expression. In our studies, we found that IIS stimulates FGT-1 protein expression by a
post-transcriptional mechanism, however, the specific mechanism remains unknown.
Further studies should focus on the regulation of FGT-1 mRNA stability, translational
efficiency, and protein degradation by IIS. Specifically, because we showed that IIS
regulation of FGT-1 expression is dependent on DAF-16 activity, the regulation of FGT1 mRNA stability, translational efficiency, and protein degradation by DAF-16 should be
investigated.
2) The study of post-translational regulation of FGT-1 by IIS. Because the
reduced FGT-1 protein levels could not explain the severely defective FGT-1 mediated
glucose uptake observed in IIS mutants (daf-2 and age-1) in our study, IIS should also
regulate FGT-1 function by post-translational mechanisms. One such mechanism may be
through glycosylation. This study showed that OGA-1, but not OGT-1, is required for
FGT-1 function. Since OGA-1 is an O-GlcNAcase, which removes glycan from proteins,
whereas OGT-1 is an O-GlcNAc transferase, which adds glycan to proteins, analyzing
the relationship between FGT-1 function and its glycosylation states as well as the
enzymes involved in FGT-1 glycosylation will be important. In addition, glycosylation
states should be analyzed in wt and IIS mutants to establish the mechanism by which IIS
regulates FGT-1 glycosylation. Moreover, glucose is an important substrate for the
glycosylation of proteins because glucose can be metabolized through the hexosamine
biosynthesis pathway (HBP) to synthesize uridine diphosphate N-acetyl-glucosamine
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(UDP-GlcNAc), which is a direct substrate of O-glycosylation (Chatham et al. 2008).
Thus, the glycosylation of FGT-1 may provide mutual feedback regulation between
glucose transport activity and O-glycosylation levels. Another possible post-translational
mechanism is changes in subcellular localization. Although our study did not show a
localization difference between FGT-1 in wt and daf-2 mutant worms, our results were
not exclusive because of technical limitations as discussed in chapter 3. Techniques that
are more sensitive and tissue-specific should be developed for this study.
3) The study of Na+-dependent glucose transport in C. elegans. Despite the
absence of SGLT homologous genes in the C. elegans genome in our BLASTP search,
phlorizin showed significant inhibition of the glucose uptake activity in C. elegans in this
study, suggesting the existence of Na+-dependent glucose transport. Identifying the
proteins that are responsible for this activity is important and may establish C. elegans as
a model to study glucose absorption from intestinal lumen. A domain search of the
sodium:solute symporter family (SSF; PF00474) in the C. elegans genome identified
some homologues of human sodium-coupled monocarboxylate transporters (SMCTs),
which transport several small monocarboxylic acids including lactate, pyruvate, short
chain fatty acids, and ketone bodies, but not glucose (Miyauchi et al. 2004; Coady et al.
2004; Yanase et al. 2008). These SMCT homologues may have broader substrate
specificity including glucose transport activity in C. elegans.
4) Last but not least, the study of IIS regulation of gluconeogenesis. Based on
the results of this study, we hypothesize that gluconeogenesis is inhibited in IIS mutants,
resulting in their dependence on FGT-1 activity. This hypothesis can be tested by
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measuring glucose synthesis rates from radiolabeled substrates in wt and IIS mutant
worms. Such observation may reveal that C. elegans can be an excellent model system to
study the mechanism by which insulin regulates gluconeogenesis.
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4.4 Figures
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Figure 4.1. A proposed model of insulin/IGF-like signaling (IIS) regulation of sugar
metabolism in Caenorhabditis elegans
Activation is indicated with arrow-headed lines, and inhibition is indicated with barheaded lines. Hypothesized regulation and transport activities are indicated with question
marks and dash lines.
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